• UNSW
  • Staff
  • Associate Professor Anthony Joshua
Back to
Associate Professor Anthony Joshua
Conjoint Professor

Associate Professor Anthony Joshua

Medicine & Health
School of Clinical Medicine

Dr Anthony Joshua completed his medical oncology training at the Royal Prince Alfred hospital in Sydney, Australia before moving to Toronto, Canada to complete a PhD under the supervision of Dr Jeremy Squire in prostatic carcinogenesis, and a clinical Fellowship under Dr Ian Tannock. 

He joined the Department of Medical Oncology at Princess Margaret Cancer Centre in Toronto as a staff oncologist in late 2008, specialising in genito-urinary malignancy and melanoma with research interests in circulating tumour DNA, tumour heterogeneity, mechanisms of enzalutamide resistance and autophagy. 

He returned to Australia, joining the Kinghorn Cancer Centre and the Garvan Institute of Medical Research in late 2015. He is currently a conjoint Associate Professor with the University of New South Wales.
Phone
0293555655
E-mail
anthony.joshua@svha.org.au
  • Book Chapters | 2020
    2020, 'Merkel Cell Carcinoma', in Surgical Oncology Manual, Springer International Publishing, pp. 333 - 343, http://dx.doi.org/10.1007/978-3-030-48363-0_17
    Book Chapters | 2020
    2020, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual, Springer International Publishing, pp. 383 - 393, http://dx.doi.org/10.1007/978-3-030-48363-0_19
    Book Chapters | 2016
    2016, 'Merkel Cell Carcinoma', in Surgical Oncology Manual, Springer International Publishing, pp. 189 - 196, http://dx.doi.org/10.1007/978-3-319-26276-5_14
    Book Chapters | 2016
    2016, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual, Springer International Publishing, pp. 225 - 232, http://dx.doi.org/10.1007/978-3-319-26276-5_17
  • Journal articles | 2023
    2023, '177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677
    Journal articles | 2023
    2023, 'Advances in the clinical management of uveal melanoma', Nature Reviews Clinical Oncology, 20, pp. 99 - 115, http://dx.doi.org/10.1038/s41571-022-00714-1
    Journal articles | 2023
    2023, 'Chemotherapy in Cutaneous Melanoma: Is There Still a Role?', Current Oncology Reports, http://dx.doi.org/10.1007/s11912-023-01385-6
    Journal articles | 2023
    2023, 'Correction To: LXS196 for Metastatic Uveal Melanoma - finally some progress (British Journal of Cancer, (2023), 10.1038/s41416-023-02199-w)', British Journal of Cancer, http://dx.doi.org/10.1038/s41416-023-02231-z
    Journal articles | 2023
    2023, 'Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398
    Journal articles | 2023
    2023, 'Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).', Journal of Clinical Oncology, 41, pp. TPS271 - TPS271, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps271
    Journal articles | 2023
    2023, 'Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma.', Cancer Res Commun, 3, pp. 267 - 280, http://dx.doi.org/10.1158/2767-9764.CRC-22-0456
    Journal articles | 2023
    2023, 'LXS196 for Metastatic Uveal Melanoma - finally some progress', British Journal of Cancer, 128, pp. 1791 - 1793, http://dx.doi.org/10.1038/s41416-023-02199-w
    Journal articles | 2023
    2023, 'Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse.', Sci Adv, 9, pp. eadf9063, http://dx.doi.org/10.1126/sciadv.adf9063
    Journal articles | 2023
    2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15, pp. 17588359231156392, http://dx.doi.org/10.1177/17588359231156392
    Journal articles | 2023
    2023, 'Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.', Journal of Clinical Oncology, 41, pp. 256 - 256, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.256
    Journal articles | 2023
    2023, 'Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).', Journal of Clinical Oncology, 41, pp. TPS296 - TPS296, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps296
    Journal articles | 2023
    2023, 'Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial', The Lancet Oncology, 24, pp. 323 - 334, http://dx.doi.org/10.1016/S1470-2045(23)00063-3
    Journal articles | 2023
    2023, 'The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104
    Journal articles | 2022
    2022, '1389P Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)', Annals of Oncology, 33, pp. S1178 - S1178, http://dx.doi.org/10.1016/j.annonc.2022.07.1521
    Journal articles | 2022
    2022, '1403P Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase I/II trial', Annals of Oncology, 33, pp. S1186 - S1187, http://dx.doi.org/10.1016/j.annonc.2022.07.1889
    Journal articles | 2022
    2022, '821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma', Annals of Oncology, 33, pp. S923 - S923, http://dx.doi.org/10.1016/j.annonc.2022.07.947
    Journal articles | 2022
    2022, '177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552
    Journal articles | 2022
    2022, 'A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer', Epigenomics, 14, pp. 811 - 822, http://dx.doi.org/10.2217/epi-2022-0103
    Journal articles | 2022
    2022, 'A review of the cutaneous toxicities of tebentafusp—Featuring two cases involving superficial bullous reactions', Australasian Journal of Dermatology, 63, pp. e279 - e282, http://dx.doi.org/10.1111/ajd.13866
    Journal articles | 2022
    2022, 'BRAF inhibition and the spectrum of granulomatous reactions', Journal of the American Academy of Dermatology, 87, pp. 605 - 613, http://dx.doi.org/10.1016/j.jaad.2021.10.030
    Journal articles | 2022
    2022, 'Clinical trials for metastatic castrate-resistant prostate cancer—who is looking after the control patients? Questions for the future', Annals of Oncology, 33, pp. 574 - 577, http://dx.doi.org/10.1016/j.annonc.2022.03.272
    Journal articles | 2022
    2022, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', BMC Medicine, 20, pp. 112, http://dx.doi.org/10.1186/s12916-022-02298-0
    Journal articles | 2022
    2022, 'Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: Interim results from a multicenter phase I/II trial', Journal for ImmunoTherapy of Cancer, 10, http://dx.doi.org/10.1136/jitc-2021-004424
    Journal articles | 2022
    2022, 'EP16.03-041 Single Cell RNA Sequencing Reveals Phenotypic Predispositions to Developing Lung Cancer in Never-Smokers', Journal of Thoracic Oncology, 17, pp. S608 - S608, http://dx.doi.org/10.1016/j.jtho.2022.07.1102
    Journal articles | 2022
    2022, 'Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302', European Journal of Cancer, 170, pp. 296 - 304, http://dx.doi.org/10.1016/j.ejca.2022.03.042
    Journal articles | 2022
    2022, 'Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue', Prostate Cancer, 2022, pp. 6499344, http://dx.doi.org/10.1155/2022/6499344
    Journal articles | 2022
    2022, 'Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer', Journal of Cancer Research and Clinical Oncology, http://dx.doi.org/10.1007/s00432-022-04391-6
    Journal articles | 2022
    2022, 'Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP', Journal of Clinical Oncology, 40, pp. 837 - 846, http://dx.doi.org/10.1200/JCO.21.00941
    Journal articles | 2022
    2022, 'KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation', European Journal of Cancer, 160, pp. 1 - 11, http://dx.doi.org/10.1016/j.ejca.2021.09.024
    Journal articles | 2022
    2022, 'Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin', Cancers, 14, http://dx.doi.org/10.3390/cancers14194792
    Journal articles | 2022
    2022, 'Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial', The Lancet Oncology, 23, pp. 362 - 373, http://dx.doi.org/10.1016/S1470-2045(21)00757-9
    Journal articles | 2022
    2022, 'PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial', The Lancet Oncology, 23, pp. 1389 - 1397, http://dx.doi.org/10.1016/S1470-2045(22)00605-2
    Journal articles | 2022
    2022, 'Patient Preference or Indifference: Learning from the CABADOC Study', European Urology, 81, pp. 241 - 242, http://dx.doi.org/10.1016/j.eururo.2021.11.005
    Journal articles | 2022
    2022, 'Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study', European Urology, 82, pp. 22 - 30, http://dx.doi.org/10.1016/j.eururo.2022.02.023
    Journal articles | 2022
    2022, 'Radiographic progression-free survival in the ACIS trial for prostate cancer', The Lancet Oncology, 23, pp. e4, http://dx.doi.org/10.1016/S1470-2045(21)00719-1
    Journal articles | 2022
    2022, 'Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer.', Cancer Res Commun, 2, pp. 293 - 306, http://dx.doi.org/10.1158/2767-9764.CRC-22-0037
    Journal articles | 2022
    2022, 'Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER', European Journal of Cancer, 170, pp. 285 - 295, http://dx.doi.org/10.1016/j.ejca.2022.04.005
    Journal articles | 2022
    2022, 'The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors', Nature Communications, 13, pp. 6467, http://dx.doi.org/10.1038/s41467-022-34012-2
    Journal articles | 2021
    2021, '351 KEYNOTE-365 cohort D: pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)', Journal for ImmunoTherapy of Cancer, 9, pp. A378 - A378, http://dx.doi.org/10.1136/jitc-2021-sitc2021.351
    Journal articles | 2021
    2021, '418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma', Journal for ImmunoTherapy of Cancer, 9, pp. A448 - A448, http://dx.doi.org/10.1136/jitc-2021-sitc2021.418
    Journal articles | 2021
    2021, '419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F', Journal for ImmunoTherapy of Cancer, 9, pp. A449 - A449, http://dx.doi.org/10.1136/jitc-2021-sitc2021.419
    Journal articles | 2021
    2021, '425 Pembrolizumab + vibostolimab in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: phase 1b/2 KEYNOTE-365 cohorts G/H', Journal for ImmunoTherapy of Cancer, 9, pp. A455 - A455, http://dx.doi.org/10.1136/jitc-2021-sitc2021.425
    Journal articles | 2021
    2021, '509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer', Journal for ImmunoTherapy of Cancer, 9, pp. A540 - A540, http://dx.doi.org/10.1136/jitc-2021-sitc2021.509
    Journal articles | 2021
    2021, '620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion', Annals of Oncology, 32, pp. S657 - S659, http://dx.doi.org/10.1016/j.annonc.2021.08.1133
    Journal articles | 2021
    2021, 'Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 with Cognitive Function in Older Men with Metastatic Castration-Resistant Prostate Cancer', JAMA Network Open, 4, http://dx.doi.org/10.1001/jamanetworkopen.2021.14694
    Journal articles | 2021
    2021, 'Barriers and facilitators related to undertaking physical activities among men with prostate cancer: a scoping review', Prostate Cancer and Prostatic Diseases, 24, pp. 1007 - 1027, http://dx.doi.org/10.1038/s41391-021-00399-0
    Journal articles | 2021
    2021, 'Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.9527
    Journal articles | 2021
    2021, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', Genome Medicine, 13, pp. 81, http://dx.doi.org/10.1186/s13073-021-00885-z
    Journal articles | 2021
    2021, 'Cutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor', Skin Health and Disease, 1, pp. e71, http://dx.doi.org/10.1002/ski2.71
    Journal articles | 2021
    2021, 'Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601).', Journal of Clinical Oncology, 39, pp. TPS367 - TPS367, http://dx.doi.org/10.1200/jco.2021.39.6_suppl.tps367
    Journal articles | 2021
    2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, 128, pp. 642 - 651, http://dx.doi.org/10.1111/bju.15491
    Journal articles | 2021
    2021, 'Emergence of enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies', Clinical Cancer Research, 27, pp. 2340 - 2351, http://dx.doi.org/10.1158/1078-0432.CCR-20-3260
    Journal articles | 2021
    2021, 'Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor–targeted therapy for metastatic castration-resistant prostate cancer', Cancer, 127, pp. 2587 - 2594, http://dx.doi.org/10.1002/cncr.33523
    Journal articles | 2021
    2021, 'Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)', ANNALS OF ONCOLOGY, 32, pp. S632 - S633, http://dx.doi.org/10.1016/j.annonc.2021.08.1095
    Journal articles | 2021
    2021, 'Initial results from a first in human trial incorporating accelerated dose titration of a novel immune stimulating oncolytic virus-VG161.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.e14574
    Journal articles | 2021
    2021, 'Ipilimumab plus nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.4565
    Journal articles | 2021
    2021, 'KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.', Journal of Clinical Oncology, 39, pp. 10 - 10, http://dx.doi.org/10.1200/jco.2021.39.6_suppl.10
    Journal articles | 2021
    2021, 'KEYNOTE-365 cohort I: Phase Ib/II study of platinum containing chemotherapy in combination with pembrolizumab and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE)', ANNALS OF ONCOLOGY, 32, pp. S669 - S669, http://dx.doi.org/10.1016/j.annonc.2021.08.1152
    Journal articles | 2021
    2021, 'Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006', European Journal of Cancer, 157, pp. 391 - 402, http://dx.doi.org/10.1016/j.ejca.2021.08.013
    Journal articles | 2021
    2021, 'Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma', European Journal of Cancer, 144, pp. 182 - 191, http://dx.doi.org/10.1016/j.ejca.2020.11.010
    Journal articles | 2021
    2021, 'Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report', Annals of Oncology, 32, pp. 280 - 282, http://dx.doi.org/10.1016/j.annonc.2020.11.006
    Journal articles | 2021
    2021, 'Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy', European Urology, 80, pp. 275 - 279, http://dx.doi.org/10.1016/j.eururo.2021.05.016
    Journal articles | 2021
    2021, 'Overall survival benefit from tebentafusp in patients with best response of progressive disease.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.9509
    Journal articles | 2021
    2021, 'Overall survival benefit with tebentafusp in metastatic uveal melanoma', New England Journal of Medicine, 385, pp. 1196 - 1206, http://dx.doi.org/10.1056/NEJMoa2103485
    Journal articles | 2021
    2021, 'Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase', EBioMedicine, 72, http://dx.doi.org/10.1016/j.ebiom.2021.103625
    Journal articles | 2021
    2021, 'Parp inhibitors in melanoma—an expanding therapeutic option?', Cancers, 13, http://dx.doi.org/10.3390/cancers13184520
    Journal articles | 2021
    2021, 'Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European urology oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002
    Journal articles | 2021
    2021, 'Phase Ib/II trial of pembrolizumab (pembro) plus lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F', ANNALS OF ONCOLOGY, 32, pp. S669 - S670, http://dx.doi.org/10.1016/j.annonc.2021.08.1153
    Journal articles | 2021
    2021, 'Phase Ib/II trial of pembrolizumab (pembro) plus vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H', ANNALS OF ONCOLOGY, 32, pp. S670 - S671, http://dx.doi.org/10.1016/j.annonc.2021.08.1154
    Journal articles | 2021
    2021, 'Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy', JOURNAL OF UROLOGY, 206, pp. 1519 - 1520, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000716572000083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2021
    2021, 'Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer', BJU International, 128, pp. 18 - 26, http://dx.doi.org/10.1111/bju.15364
    Journal articles | 2021
    2021, 'Relationship between circulating lipids and cytokines in metastatic castration‐resistant prostate cancer', Cancers, 13, pp. 4964 - 4964, http://dx.doi.org/10.3390/cancers13194964
    Journal articles | 2021
    2021, 'Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 39, pp. TPS5088 - TPS5088, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps5088
    Journal articles | 2021
    2021, 'Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer', European Urology, 79, pp. 177 - 179, http://dx.doi.org/10.1016/j.eururo.2020.09.048
    Journal articles | 2021
    2021, 'To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma', Cancer, 127, pp. 2333 - 2341, http://dx.doi.org/10.1002/cncr.33499
    Journal articles | 2021
    2021, 'Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease', Asia-Pacific Journal of Clinical Oncology, 17, pp. 36 - 42, http://dx.doi.org/10.1111/ajco.13447
    Journal articles | 2021
    2021, 'UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)', BJU International, 128, pp. 331 - 342, http://dx.doi.org/10.1111/bju.15384
    Journal articles | 2021
    2021, 'Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer', Translational Andrology and Urology, 10, pp. 1688 - 1699, http://dx.doi.org/10.21037/tau-20-1444
    Journal articles | 2021
    2021, '[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial', The Lancet, 397, pp. 797 - 804, http://dx.doi.org/10.1016/S0140-6736(21)00237-3
    Journal articles | 2020
    2020, '1143P Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials', Annals of Oncology, 31, pp. S764 - S764, http://dx.doi.org/10.1016/j.annonc.2020.08.1266
    Journal articles | 2020
    2020, '2017 ASCO position on the affordability of cancer drugs: Arguments for a major revision', JCO Oncology Practice, 16, pp. 211 - 214, http://dx.doi.org/10.1200/JOP.19.00763
    Journal articles | 2020
    2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', Journal of Clinical Oncology, 38, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3073
    Journal articles | 2020
    2020, 'Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies', Hormones and Cancer, 11, pp. 155 - 169, http://dx.doi.org/10.1007/s12672-020-00385-3
    Journal articles | 2020
    2020, 'Cancer patients’ experiences with immune checkpoint modulators: A qualitative study', Cancer Medicine, 9, pp. 3015 - 3022, http://dx.doi.org/10.1002/cam4.2940
    Journal articles | 2020
    2020, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', bioRxiv, http://dx.doi.org/10.1101/2020.06.04.135277
    Journal articles | 2020
    2020, 'Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment', Epigenomics, 12, pp. 1317 - 1332, http://dx.doi.org/10.2217/epi-2020-0173
    Journal articles | 2020
    2020, 'Fats and mets, KRAS-driven lipid dysregulation affects metastatic potential in pancreatic cancer', Cancer Research, 80, pp. 4886 - 4887, http://dx.doi.org/10.1158/0008-5472.CAN-20-3082
    Journal articles | 2020
    2020, 'Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial', European Urology, 78, pp. 347 - 357, http://dx.doi.org/10.1016/j.eururo.2020.04.061
    Journal articles | 2020
    2020, 'Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma', ANNALS OF ONCOLOGY, 31, pp. S762 - S763, http://dx.doi.org/10.1016/j.annonc.2020.08.1262
    Journal articles | 2020
    2020, 'Oncology in 2050 – A Retrospective?', Oncologist, 25, pp. e1127 - e1130, http://dx.doi.org/10.1634/theoncologist.2019-0887
    Journal articles | 2020
    2020, 'Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study', ANNALS OF ONCOLOGY, 31, pp. S1325 - S1325, http://dx.doi.org/10.1016/j.annonc.2020.10.437
    Journal articles | 2020
    2020, 'Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.', Journal of Clinical Oncology, 38, pp. 5550 - 5550, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5550
    Journal articles | 2020
    2020, 'Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update', ANNALS OF ONCOLOGY, 31, pp. S512 - S513, http://dx.doi.org/10.1016/j.annonc.2020.08.879
    Journal articles | 2020
    2020, 'Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)', BMJ Open, 10, http://dx.doi.org/10.1136/bmjopen-2019-033667
    Journal articles | 2020
    2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120
    Journal articles | 2020
    2020, 'The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 38, pp. 73 - 73, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.73
    Journal articles | 2020
    2020, 'The end of pathology as we know it? (vol 47, pg 163, 2019)', CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 48, pp. 274 - 274, http://dx.doi.org/10.1111/ceo.13720
    Journal articles | 2020
    2020, 'The impact of whole genome data on therapeutic decision‐making in metastatic prostate cancer: A retrospective analysis', Cancers, 12, http://dx.doi.org/10.3390/cancers12051178
    Journal articles | 2020
    2020, 'TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).', Journal of Clinical Oncology, 38, pp. 5500 - 5500, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5500
    Journal articles | 2020
    2020, 'Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.', Journal of Clinical Oncology, 38, pp. 78 - 78, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.78
    Journal articles | 2020
    2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557
    Journal articles | 2019
    Sattar S; Alibhai SM H; Brennenstuhl S; Kulik M; MacDonald ME; McWatters K; Lee K; Jang R; Amir E; Krzyzanowska MK; Joshua AM; Monette J; Wan-Chow-Wah D; Puts MT E, 2019, 'Health status, emergency department visits, and oncologists’ feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trial', Journal of Geriatric Oncology, 10, pp. 169 - 174, http://dx.doi.org/10.1016/j.jgo.2018.06.014
    Journal articles | 2019
    2019, 'A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205', Clinical Genitourinary Cancer, 17, pp. 201 - 208.e1, http://dx.doi.org/10.1016/j.clgc.2019.03.005
    Journal articles | 2019
    2019, 'A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial', British Journal of Cancer, 120, pp. 1113 - 1119, http://dx.doi.org/10.1038/s41416-019-0474-x
    Journal articles | 2019
    2019, 'Author Correction: Therapeutic implications of germline genetic findings in cancer (Nature Reviews Clinical Oncology, (2019), 16, 6, (386-396), 10.1038/s41571-019-0179-3)', Nature Reviews Clinical Oncology, 16, pp. 397, http://dx.doi.org/10.1038/s41571-019-0212-6
    Journal articles | 2019
    2019, 'BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).', Journal of Clinical Oncology, 37, pp. 358 - 358, http://dx.doi.org/10.1200/jco.2019.37.7_suppl.358
    Journal articles | 2019
    2019, 'Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup', European Urology Supplements, 18, pp. e1509 - e1510, http://dx.doi.org/10.1016/s1569-9056(19)31087-5
    Journal articles | 2019
    2019, 'Companion Diagnostics to Identify Biomarkers of Response to Anticancer Drugs Targeting the Proteome', Cancer Cell, 36, pp. 464 - 465, http://dx.doi.org/10.1016/j.ccell.2019.10.003
    Journal articles | 2019
    2019, 'Conjunctival Melanoma in Childhood and Adolescence: A Systematic Review', Ocular Oncology and Pathology, 5, pp. 387 - 395, http://dx.doi.org/10.1159/000497813
    Journal articles | 2019
    2019, 'Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials', European Journal of Cancer, 107, pp. 1 - 7, http://dx.doi.org/10.1016/j.ejca.2018.10.017
    Journal articles | 2019
    2019, 'Developing a pan-cancer research autopsy programme', Journal of Clinical Pathology, 72, pp. 689 - 695, http://dx.doi.org/10.1136/jclinpath-2019-205874
    Journal articles | 2019
    2019, 'Embedding Research (and Evidence) in Cancer Healthcare - EnRICH', JOURNAL OF THORACIC ONCOLOGY, 14, pp. S606 - S606, http://dx.doi.org/10.1016/j.jtho.2019.08.1273
    Journal articles | 2019
    2019, 'Enzalutamide with standard first-line therapy in metastatic prostate cancer', New England Journal of Medicine, 381, pp. 121 - 131, http://dx.doi.org/10.1056/NEJMoa1903835
    Journal articles | 2019
    2019, 'Exceptional response to 177lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237
    Journal articles | 2019
    2019, 'Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001', Annals of Oncology, 30, pp. 582 - 588, http://dx.doi.org/10.1093/annonc/mdz011
    Journal articles | 2019
    2019, 'Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities', Cancer, 125, pp. 1341 - 1349, http://dx.doi.org/10.1002/cncr.31999
    Journal articles | 2019
    2019, 'Immune checkpoint inhibitors in malignancy', Australian Prescriber, 42, pp. 62 - 67, http://dx.doi.org/10.18773/austprescr.2019.012
    Journal articles | 2019
    2019, 'Implementation of the Australasian Teletrial Model: Lessons from practice', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15, pp. 3 - 14, http://dx.doi.org/10.1111/ajco.13249
    Journal articles | 2019
    2019, 'Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 37, pp. 145 - 145, http://dx.doi.org/10.1200/jco.2019.37.7_suppl.145
    Journal articles | 2019
    2019, 'Managing ocular surface neoplasia without biopsy: The end of pathology as we know it?', Clinical and Experimental Ophthalmology, 47, pp. 163 - 164, http://dx.doi.org/10.1111/ceo.13475
    Journal articles | 2019
    2019, 'Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: An international rare cancers initiative (IRCI) ocular melanoma study', Annals of Oncology, 30, pp. 1370 - 1380, http://dx.doi.org/10.1093/annonc/mdz176
    Journal articles | 2019
    2019, 'Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center', Asia-Pacific Journal of Clinical Oncology, 15, pp. 257 - 261, http://dx.doi.org/10.1111/ajco.13148
    Journal articles | 2019
    2019, 'PD47-01 BMS-986205, AN INDOLEAMINE 2,3-DIOXYGENASE 1 INHIBITOR, PLUS NIVOLUMAB: UPDATED SAFETY ACROSS ALL TUMOR COHORTS AND EFFICACY IN ADVANCED BLADDER CANCER', Journal of Urology, 201, http://dx.doi.org/10.1097/01.ju.0000556757.85628.f0
    Journal articles | 2019
    2019, 'PERCEPTION OF STRUCTURED EXERCISE PROGRAMS AND FACTORS ASSOCIATED WITH PARTICIPATION AND ADHERENCE AMONG MEN WITH PROSTATE CANCER: A SCOPING REVIEW', Journal of Geriatric Oncology, 10, pp. S98 - S98, http://dx.doi.org/10.1016/s1879-4068(19)31282-2
    Journal articles | 2019
    2019, 'Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)', Oncologist, 24, pp. 1188 - 1194, http://dx.doi.org/10.1634/theoncologist.2018-0621
    Journal articles | 2019
    2019, 'Patterns of Care in a Prospective Clinical Cohort of Patients with Lung Cancer - Preliminary Analyses from the EnRICH Program', JOURNAL OF THORACIC ONCOLOGY, 14, pp. S880 - S880, http://dx.doi.org/10.1016/j.jtho.2019.08.1903
    Journal articles | 2019
    2019, 'Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5029
    Journal articles | 2019
    2019, 'Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5010
    Journal articles | 2019
    2019, 'Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5027
    Journal articles | 2019
    2019, 'Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2', Cancer Immunology, Immunotherapy, 68, pp. 773 - 785, http://dx.doi.org/10.1007/s00262-019-02307-x
    Journal articles | 2019
    2019, 'Phenotypic profiling of circulating tumor cells in metastatic prostate cancer patients using nanoparticle-mediated ranking', Analytical Chemistry, 91, pp. 9348 - 9355, http://dx.doi.org/10.1021/acs.analchem.9b01697
    Journal articles | 2019
    2019, 'Psychological Distress in Never, Ex, Current, and Passive Smokers Diagnosed with Lung Cancer - Analyses from the EnRICH Program', JOURNAL OF THORACIC ONCOLOGY, 14, pp. S326 - S327, http://dx.doi.org/10.1016/j.jtho.2019.08.656
    Journal articles | 2019
    2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099
    Journal articles | 2019
    2019, 'Results of a Prospective Phase 2 Pilot Trial of 177 Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014
    Journal articles | 2019
    2019, 'Survival in early phase immuno-oncology trials: Development and validation of a prognostic index', JNCI Cancer Spectrum, 3, http://dx.doi.org/10.1093/jncics/pkz071
    Journal articles | 2019
    2019, 'The Australian Exceptional Responders Program: A national collaboration', Annals of Oncology, 30, pp. v794 - v795, http://dx.doi.org/10.1093/annonc/mdz268.104
    Journal articles | 2019
    2019, 'Therapeutic implications of germline genetic findings in cancer', Nature Reviews Clinical Oncology, 16, pp. 386 - 396, http://dx.doi.org/10.1038/s41571-019-0179-3
    Journal articles | 2019
    2019, 'Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options', Asia-Pacific Journal of Clinical Oncology, 15, pp. 3 - 10, http://dx.doi.org/10.1111/ajco.13289
    Journal articles | 2019
    2019, 'Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents.', Journal of Clinical Oncology, 37, pp. 11510 - 11510, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.11510
    Journal articles | 2018
    Benidir T; Hersey K; Finelli A; Hamilton R; Joshua AM; Kulkarni G; Zlotta A; Fleshner N, 2018, 'Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer', Urologic Oncology: Seminars and Original Investigations, 36, pp. 240.e13 - 240.e20, http://dx.doi.org/10.1016/j.urolonc.2018.01.011
    Journal articles | 2018
    Crumbaker M; Savdie R; Joshua AM, 2018, 'Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer', European Urology, 73, pp. 736 - 737, http://dx.doi.org/10.1016/j.eururo.2017.11.005
    Journal articles | 2018
    Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DY C; Sweeney CJ, 2018, 'Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer', Clinical Genitourinary Cancer, 16, pp. 130 - 134, http://dx.doi.org/10.1016/j.clgc.2017.12.012
    Journal articles | 2018
    Gordevicius J; Krisci unas A; Groot DE; Yip SM; Susic M; Kwan A; Kustra R; Joshua AM; Chi KN; Petronis A; Oh G, 2018, 'Cell-free DNA modification dynamics in abiraterone acetate-treated prostate cancer patients', Clinical Cancer Research, 24, pp. 3317 - 3324, http://dx.doi.org/10.1158/1078-0432.CCR-18-0101
    Journal articles | 2018
    Joseph RW; Elassaiss-Schaap J; Kefford R; Hwu WJ; Wolchok JD; Joshua AM; Ribas A; Hodi FS; Hamid O; Robert C; Daud A; Dronca R; Hersey P; Weber JS; Patnaik A; De Alwis DP; Perrone A; Zhang J; Kang SP; Ebbinghaus S; Anderson KM; Gangadhar TC, 2018, 'Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab', Clinical Cancer Research, 24, pp. 4960 - 4967, http://dx.doi.org/10.1158/1078-0432.CCR-17-2386
    Journal articles | 2018
    Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM, 2018, 'Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience', Melanoma Research, 28, pp. 571 - 577, http://dx.doi.org/10.1097/CMR.0000000000000468
    Journal articles | 2018
    Park JJ; Diefenbach RJ; Joshua AM; Kefford RF; Carlino MS; Rizos H, 2018, 'Oncogenic signaling in uveal melanoma', Pigment Cell and Melanoma Research, 31, pp. 661 - 672, http://dx.doi.org/10.1111/pcmr.12708
    Journal articles | 2018
    Puts MT E; Sattar S; Kulik M; MacDonald ME; McWatters K; Lee K; Brennenstuhl S; Jang R; Amir E; Krzyzanowska MK; Joshua AM; Monette J; Wan-Chow-Wah D; Alibhai SM H, 2018, 'A randomized phase II trial of geriatric assessment and management for older cancer patients', Supportive Care in Cancer, 26, pp. 109 - 117, http://dx.doi.org/10.1007/s00520-017-3820-7
    Journal articles | 2018
    Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS, 2018, 'Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma', Journal of Clinical Oncology, 36, pp. 1668 - 1674, http://dx.doi.org/10.1200/JCO.2017.75.6270
    Journal articles | 2018
    Tannock IF; Joshua AM, 2018, 'Purchasing silence', Annals of Oncology, 29, pp. 1339 - 1340, http://dx.doi.org/10.1093/annonc/mdy131
    Journal articles | 2018
    Tio M; Rai R; Ezeoke OM; McQuade JL; Zimmer L; Khoo C; Park JJ; Spain L; Turajlic S; Ardolino L; Yip D; Goldinger SM; Cohen JV; Millward M; Atkinson V; Kane AY; Ascierto PA; Garbe C; Gutzmer R; Johnson DB; Rizvi HA; Joshua AM; Hellmann MD; Long GV; Menzies AM, 2018, 'Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection', European Journal of Cancer, 104, pp. 137 - 144, http://dx.doi.org/10.1016/j.ejca.2018.09.017
    Journal articles | 2018
    Yu EY; Ellard SL; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME; Chi KN, 2018, 'A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer', Investigational New Drugs, 36, pp. 278 - 287, http://dx.doi.org/10.1007/s10637-017-0553-x
    Journal articles | 2018
    2018, '5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.', Journal of Clinical Oncology, 36, pp. 9516 - 9516, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.9516
    Journal articles | 2018
    2018, 'BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).', Journal of Clinical Oncology, 36, pp. 4512 - 4512, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.4512
    Journal articles | 2018
    2018, 'Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)', Clinical Cancer Research, 24, pp. 6098, http://dx.doi.org/10.1158/1078-0432.CCR-18-3340
    Journal articles | 2018
    2018, 'Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer', Future Science OA, 4, http://dx.doi.org/10.4155/fsoa-2017-0094
    Journal articles | 2018
    2018, 'Minimally invasive real-time detection of actionable mutations in patients with metastatic solid tumors using fine-needle and liquid biopsies', JCO Precision Oncology, 2, pp. 1 - 20, http://dx.doi.org/10.1200/PO.17.00248
    Journal articles | 2018
    2018, 'Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial', Annals of oncology : official journal of the European Society for Medical Oncology, 29, pp. viii279 - viii280, http://dx.doi.org/10.1093/annonc/mdy284.018
    Journal articles | 2017
    Atkinson TM; Hay JL; Shoushtari A; Li Y; Paucar DJ; Smith SC; Kudchadkar RR; Doyle A; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Marr B; Abramson DH; Dickson MA; Schwartz GK; Carvajal RD, 2017, 'Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma', Journal of Cancer Research and Clinical Oncology, 143, pp. 439 - 445, http://dx.doi.org/10.1007/s00432-016-2318-x
    Journal articles | 2017
    Emmett L; Van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P, 2017, 'Treatment outcomes from 68Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: Prognostic value of a negative PSMA PET', Journal of Nuclear Medicine, 58, pp. 1972 - 1976, http://dx.doi.org/10.2967/jnumed.117.196683
    Journal articles | 2017
    Gwadry-Sridhar F; Nikan S; Hamou A; Seung SJ; Petrella T; Joshua AM; Ernst S; Mittmann N, 2017, 'Resource utilization and costs of managing patients with advanced melanoma: A canadian population-based study', Current Oncology, 24, pp. 168 - 175, http://dx.doi.org/10.3747/co.24.3432
    Journal articles | 2017
    Liang Y; Ahmed M; Guo H; Soares F; Hua JT; Gao S; Lu C; Poon C; Han W; Langstein J; Ekram MB; Li B; Davicioni E; Takhar M; Erho N; Karnes RJ; Chadwick D; Van Der Kwast T; Boutros PC; Arrowsmith CH; Feng FY; Joshua AM; Zoubeidi A; Cai C; He HH, 2017, 'LSD1-mediated epigenetic reprogramming drives CENPE expression and prostate cancer progression', Cancer Research, 77, pp. 5479 - 5490, http://dx.doi.org/10.1158/0008-5472.CAN-17-0496
    Journal articles | 2017
    Montgomery B; Tretiakova MS; Joshua AM; Gleave ME; Fleshner N; Bubley GJ; Mostaghel EA; Chi KN; Lin DW; Sanda M; Novotny W; Wu K; Kantoff PW; Marck BT; Plymate S; Balk SP; Nelson PS; Matsumoto AM; Lis RT; Kibel A; Haas GP; Krivoshik A; Hannah A; Taplin ME, 2017, 'Neoadjuvant enzalutamide prior to prostatectomy', Clinical Cancer Research, 23, pp. 2169 - 2176, http://dx.doi.org/10.1158/1078-0432.CCR-16-1357
    Journal articles | 2017
    Pitcher B; Khoja L; Hamilton RJ; Abdallah K; Pintilie M; Joshua AM, 2017, 'Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)', PLoS ONE, 12, http://dx.doi.org/10.1371/journal.pone.0170544
    Journal articles | 2017
    Poudineh M; Aldridge PM; Ahmed S; Green BJ; Kermanshah L; Nguyen V; Tu C; Mohamadi RM; Nam RK; Hansen A; Sridhar SS; Finelli A; Fleshner NE; Joshua AM; Sargent EH; Kelley SO, 2017, 'Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking', Nature Nanotechnology, 12, pp. 274 - 281, http://dx.doi.org/10.1038/nnano.2016.239
    Journal articles | 2017
    Puts MT E; Sattar S; McWatters K; Lee K; Kulik M; MacDonald ME; Jang R; Amir E; Krzyzanowska MK; Leighl N; Fitch M; Joshua AM; Warde P; Tourangeau AE; Alibhai SM H, 2017, 'Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study', Supportive Care in Cancer, 25, pp. 879 - 886, http://dx.doi.org/10.1007/s00520-016-3476-8
    Journal articles | 2017
    Tan Q; Joshua AM; Wang M; Bristow RG; Wouters BG; Allen CJ; Tannock IF, 2017, 'Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity', Cancer Chemotherapy and Pharmacology, 79, pp. 959 - 969, http://dx.doi.org/10.1007/s00280-017-3298-5
    Journal articles | 2017
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN, 2017, 'AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate', Journal of Urology, 197, pp. 135 - 142, http://dx.doi.org/10.1016/j.juro.2016.06.094
    Journal articles | 2017
    2017, 'AR signaling and the PI3K pathway in prostate cancer', Cancers, 9, http://dx.doi.org/10.3390/cancers9040034
    Journal articles | 2017
    2017, 'Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination', Annals of Oncology, 28, pp. v132 - v132, http://dx.doi.org/10.1093/annonc/mdx367.030
    Journal articles | 2017
    2017, 'Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT plus Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry', ANNALS OF ONCOLOGY, 28, http://dx.doi.org/10.1093/annonc/mdx370.023
    Journal articles | 2017
    2017, 'Strategies to minimize wastage of expensive drugs in expensive times: Cabazitaxel, a single center experience.', Journal of Clinical Oncology, 35, pp. e18297 - e18297, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18297
    Journal articles | 2017
    2017, 'Validating prognostic models in metastatic uveal melanoma (MUM), an international rare cancers initiative', Annals of Oncology, 28, pp. v439 - v439, http://dx.doi.org/10.1093/annonc/mdx377.025
    Journal articles | 2016
    Chi KN; Kheoh T; Ryan CJ; Molina A; Bellmunt J; Vogelzang NJ; Rathkopf DE; Fizazi K; Kantoff PW; Li J; Azad AA; Eigl BJ; Heng DY C; Joshua AM; de Bono JS; Scher HI, 2016, 'A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel', Annals of Oncology, 27, pp. 454 - 460, http://dx.doi.org/10.1093/annonc/mdv594
    Journal articles | 2016
    Corfield J; Crozier J; Joshua A; Bolton D; Lawrentschuck N, 2016, 'Understanding the role of new systemic agents in the treatment of prostate cancer', BJU International, 118, pp. 8 - 13, http://dx.doi.org/10.1111/bju.13633
    Journal articles | 2016
    Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O, 2016, 'Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma', Journal of Clinical Oncology, 34, pp. 4102 - 4109, http://dx.doi.org/10.1200/JCO.2016.67.2477
    Journal articles | 2016
    Ernst DS; Petrella T; Joshua AM; Hamou A; Thabane M; Vantyghem S; Gwadry-Sridhar F, 2016, 'Burden of illness for metastatic melanoma in Canada, 2011–2013', Current Oncology, 23, pp. e563 - e570, http://dx.doi.org/10.3747/co.23.3161
    Journal articles | 2016
    Hageman MG J S; Bossen JK; Neuhaus V; Mudgal CS; Ring D; Joshua AM; Adams J; Arbelaez GF; Aspard T; Balfour GW; Bamberger BH; Romero JC B; Baskies M; Batson AW; Baxamusa T; De Bedout R; Beldner S; Benhaim P; Benson L; Boretto JG; Boyer M; Dee GB; Calfee RP; Zambrano CG C; Cassidy C; Catalano L; Chivers K; Costanzo RM; Dantuluri P; DeSilva G; Dodds S; Evans JP; Escobar LF N; Fernandes CH; Fischer TJ; Fischer J; Fricker RM; Frykman GK; Garcia AE; Gaston GR; Giovanni Di FJ; Goldfarb CA; Grafe MW; Grunwald HW; Hammert WC; Hauck R; Hernandez RG; Hofmeister E; Hutchison RL; Ilyas A; Isaacs J; Jacoby SM; Jebson P; Jones CM; Jones M; Kakar S; Kalainov DM; Thomas KD; Kaplan S; Katolik L; Kennedy SA; Kessler MW; Kimball HL; Kraan GA; Martineau PA; McAuliffe J; McCabe SJ; McKee DM; Merrell G; Metzger C; Nancollas M; Nelson DL; Nyszkiewicz R; Ortiz JA; Owens PW; Palmer JM; Paz L; Pess GM; Polatsch D; Frank Raia J; Richard MJ; Rizzo M; Rozental ; Ruchelsman D; Semenkin OM; Aguilar JF S; Siff T; Sodha S; Spath C; Spruijt S; Stackhouse TG; Swigart C; Szabo RM; Taras J; Tavakolian JD; Terrono AL; Varecka TF; Wahegaonkar AL; Walsh CJ; Walter FL, 2016, 'Assessment of decisional conflict about the treatment of carpal tunnel syndrome, comparing patients and physicians', Archives of Bone and Joint Surgery, 4, pp. 150 - 155
    Journal articles | 2016
    Hodi FS; Hwu WJ; Kefford R; Weber JS; Daud A; Hamid O; Patnaik A; Ribas A; Robert C; Gangadhar TC; Joshua AM; Hersey P; Dronca R; Joseph R; Hille D; Xue D; Li XN; Kang SP; Ebbinghaus S; Perrone A; Wolchok JD, 2016, 'Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab', Journal of Clinical Oncology, 34, pp. 1510 - 1517, http://dx.doi.org/10.1200/JCO.2015.64.0391
    Journal articles | 2016
    Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM, 2016, 'The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma', Cancer Medicine, 5, pp. 2792 - 2799, http://dx.doi.org/10.1002/cam4.878
    Journal articles | 2016
    Khoja L; Atenafu EG; Ye Q; Gedye C; Chappell M; Hogg D; Butler MO; Joshua AM, 2016, 'Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma', Oncology Letters, 11, pp. 1581 - 1585, http://dx.doi.org/10.3892/ol.2015.4069
    Journal articles | 2016
    Khoja L; Kibiro M; Metser U; Gedye C; Hogg D; Butler MO; Atenafu EG; Joshua AM, 2016, 'Patterns of response to anti-PD-1 treatment: An exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients', British Journal of Cancer, 115, pp. 1186 - 1192, http://dx.doi.org/10.1038/bjc.2016.308
    Journal articles | 2016
    Khoja L; Maurice C; Chappell M; Macmillan L; Al-Habeeb AS; Al-Faraidy N; Butler MO; Rogalla P; Mason W; Joshua AM; Hogg D, 2016, 'Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma', Cancer Immunology Research, 4, pp. 175 - 178, http://dx.doi.org/10.1158/2326-6066.CIR-15-0186
    Journal articles | 2016
    Leibowitz-Amit R; Pintilie M; Khoja L; Azad AA; Berger R; Laird AD; Aftab DT; Chi KN; Joshua AM, 2016, 'Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: A post hoc analysis of an extension cohort of a phase II trial', Journal of Translational Medicine, 14, http://dx.doi.org/10.1186/s12967-015-0747-y
    Journal articles | 2016
    Manokumar T; Aziz S; Breunis H; Rizvi SF; Joshua AM; Tannock IF; Alibhai SM H, 2016, 'A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone', Journal of Geriatric Oncology, 7, pp. 81 - 89, http://dx.doi.org/10.1016/j.jgo.2016.01.003
    Journal articles | 2016
    Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF, 2016, 'Study of testosterone-guided androgen deprivation therapy in management of prostate cancer', Prostate, 76, pp. 235 - 242, http://dx.doi.org/10.1002/pros.23117
    Journal articles | 2016
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C, 2016, 'Association of pembrolizumab with tumor response and survival among patients with advanced melanoma', JAMA - Journal of the American Medical Association, 315, pp. 1600 - 1609, http://dx.doi.org/10.1001/jama.2016.4059
    Journal articles | 2016
    Singnurkar A; Wang J; Joshua AM; Langer DL; Metser U, 2016, '18F-FDG-PET/CT in the staging and management of melanoma a prospective multicenter Ontario PET registry study', Clinical Nuclear Medicine, 41, pp. 189 - 193, http://dx.doi.org/10.1097/RLU.0000000000000996
    Journal articles | 2016
    Smith AD; Truong M; Bristow R; Yip P; Milosevic MF; Joshua AM, 2016, 'The utility of serum ca9 for prognostication in prostate cancer', Anticancer Research, 36, pp. 4489 - 4492, http://dx.doi.org/10.21873/anticanres.10994
    Journal articles | 2016
    Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR A; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL, 2016, 'Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: The Princess Margaret IMPACT/COMPACT trial', Genome Medicine, 8, http://dx.doi.org/10.1186/s13073-016-0364-2
    Journal articles | 2016
    2016, '774 ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI)', European Urology Supplements, 15, pp. e774 - e774, http://dx.doi.org/10.1016/s1569-9056(16)60776-5
    Journal articles | 2016
    2016, 'Correlation of AR-V7 expression in whole blood with efficacy of abiraterone acetate (ABI) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).', Journal of Clinical Oncology, 34, pp. e23075 - e23075, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.e23075
    Journal articles | 2016
    2016, 'Local Tumor Flare Following Radiosurgery and Ipilimumab (Ipi) for Melanoma Brain Metastases: Increased Immune Response?', RADIOTHERAPY AND ONCOLOGY, 118, pp. S26 - S26, http://dx.doi.org/10.1016/s0167-8140(16)30053-6
    Journal articles | 2016
    2016, 'Meta-analysis of phase II trials in metastatic uveal melanoma (MUM) to determine progression-free (PFS) and overall survival (OS) benchmarks for future phase II trials: An irci-ocular melanoma initiative.', Journal of Clinical Oncology, 34, pp. 9567 - 9567, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.9567
    Journal articles | 2016
    2016, 'PD28-04 DETECTION OF ANDROGEN RECEPTOR VARIANT 7 (AR-V7) IN WHOLE BLOOD RNA OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS TREATED WITH ABIRATERONE ACETATE (ABI)', Journal of Urology, 195, http://dx.doi.org/10.1016/j.juro.2016.02.391
    Journal articles | 2016
    2016, 'Prognosticators of first line treatment for metastatic uveal melanoma (MUM).', Journal of Clinical Oncology, 34, pp. 9570 - 9570, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.9570
    Journal articles | 2016
    2016, 'Survie à 3 ans des patients traités pour mélanome métastatique par prembrolizumab (Keynote-001) et devenir des patients en réponse complète', Annales de Dermatologie et de Vénéréologie, 143, pp. S209 - S210, http://dx.doi.org/10.1016/j.annder.2016.09.264
    Journal articles | 2016
    2016, 'Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.', Journal of Clinical Oncology, 34, pp. 9503 - 9503, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.9503
    Journal articles | 2015
    Attard G; De Bono JS; Logothetis CJ; Fizazi K; Mukherjee SD; Joshua AM; Schrijvers D; Van Den Eertwegh AJ M; Li W; Molina A; Griffin TW; Kheoh T; Ricci DS; Zelinsky K; Rathkopf DE; Scher HI; Ryan CJ, 2015, 'Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate', Clinical Cancer Research, 21, pp. 1621 - 1627, http://dx.doi.org/10.1158/1078-0432.CCR-14-1961
    Journal articles | 2015
    Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY C; Joshua AM; Chi KN, 2015, 'Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status', European Urology, 67, pp. 441 - 447, http://dx.doi.org/10.1016/j.eururo.2014.01.030
    Journal articles | 2015
    Chi K; Hotte SJ; Joshua AM; North S; Wyatt AW; Collins LL; Saad F, 2015, 'Treatment of mCRPC in the AR-axis-targeted therapy-resistant state', Annals of Oncology, 26, pp. 2044 - 2056, http://dx.doi.org/10.1093/annonc/mdv267
    Journal articles | 2015
    Joshua AM; Monzon JG; Mihalcioiu C; Hogg D; Smylie M; Cheng T, 2015, 'A phase 2 study of tremelimumab in patients with advanced uveal melanoma', Melanoma Research, 25, pp. 342 - 347, http://dx.doi.org/10.1097/CMR.0000000000000175
    Journal articles | 2015
    Joshua AM; Shore ND; Saad F; Chi KN; Olsson CA; Emmenegger U; Scholz M; Berry W; Mukherjee SD; Winquist E; Haas NB; Foley MA; Dmuchowski C; Perabo F; Hirmand M; Hasabou N; Rathkopf D, 2015, 'Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America', Prostate, 75, pp. 836 - 844, http://dx.doi.org/10.1002/pros.22965
    Journal articles | 2015
    Khoja L; Butler MO; Chappell MA; Hogg D; Joshua AM, 2015, 'Increased treatment-related toxicity subsequent to an anti–PD-1 agent', Current Oncology, 22, pp. e320 - e322, http://dx.doi.org/10.3747/co.22.2418
    Journal articles | 2015
    Khoja L; Butler MO; Kang SP; Ebbinghaus S; Joshua AM, 2015, 'Pembrolizumab', Journal for ImmunoTherapy of Cancer, 3, http://dx.doi.org/10.1186/s40425-015-0078-9
    Journal articles | 2015
    Leibowitz-Amit R; Khoja L; Tannock IF; Joshua AM, 2015, 'Choosing a better end point for trials of bone-protective agents', Annals of Oncology, 26, pp. 1032 - 1033, http://dx.doi.org/10.1093/annonc/mdv039
    Journal articles | 2015
    Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM, 2015, 'Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer', Journal of Geriatric Oncology, 6, pp. 23 - 28, http://dx.doi.org/10.1016/j.jgo.2014.09.183
    Journal articles | 2015
    Manusow JS; Khoja L; Pesin N; Joshua AM; Mandelcorn ED, 2015, 'Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma', Journal for ImmunoTherapy of Cancer, 2, http://dx.doi.org/10.1186/s40425-014-0041-1
    Journal articles | 2015
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF A; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE, 2015, 'Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study', The Lancet Oncology, 16, pp. 152 - 160, http://dx.doi.org/10.1016/S1470-2045(14)71205-7
    Journal articles | 2015
    Seah JA; Leibowitz-Amit R; Atenafu EG; Alimohamed N; Knox JJ; Joshua AM; Sridhar SS, 2015, 'Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer', Clinical Genitourinary Cancer, 13, pp. e229 - e233, http://dx.doi.org/10.1016/j.clgc.2015.02.001
    Journal articles | 2015
    Sridhar SS; Joshua AM; Gregg R; Booth CM; Murray N; Golubovic J; Wang L; Harris P; Chi KN, 2015, 'A phase II study of GW786034 (Pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer', Clinical Genitourinary Cancer, 13, pp. 124 - 129, http://dx.doi.org/10.1016/j.clgc.2014.06.001
    Journal articles | 2015
    Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Kanga N; Zhang JY; Chen X; Wouters BG; Tannock IF, 2015, 'Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy', British Journal of Cancer, 112, pp. 832 - 840, http://dx.doi.org/10.1038/bjc.2015.17
    Journal articles | 2015
    2015, '2015 CUA Abstracts', Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 9, pp. S13 - S134
    Journal articles | 2015
    2015, 'A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.', Journal of Clinical Oncology, 33, pp. TPS9089 - TPS9089, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps9089
    Journal articles | 2015
    2015, 'A feasibility trial of geriatric assessment and integrated care plan for older cancer patients.', Journal of Clinical Oncology, 33, pp. TPS9634 - TPS9634, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps9634
    Journal articles | 2015
    2015, 'Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.', Journal of Clinical Oncology, 33, pp. 9050 - 9050, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9050
    Journal articles | 2015
    2015, 'Brain radiosurgery and ipilimumab (Ipi) in melanoma brain metastases (MBM) patients: Does an enhanced immune response induce radionecrosis (RN)?', Journal of Clinical Oncology, 33, pp. e20019 - e20019, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e20019
    Journal articles | 2015
    2015, 'Does frailty affect response to chemotherapy in older men with metastatic castration-resistant prostate cancer?', Journal of Clinical Oncology, 33, pp. e20528 - e20528, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e20528
    Journal articles | 2015
    2015, 'Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.', Journal of Clinical Oncology, 33, pp. 5036 - 5036, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5036
    Journal articles | 2015
    2015, 'Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.', Journal of Clinical Oncology, 33, pp. 9005 - 9005, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9005
    Journal articles | 2015
    2015, 'MP73-02 PATIENT UNDERSTANDING REGARDING END-OF-LIFE PROSTATE CANCER AND PERSPECTIVES REGARDING COST/BENEFIT OF CURRENT TREATMENT PARADIGMS', Journal of Urology, 193, http://dx.doi.org/10.1016/j.juro.2015.02.2678
    Journal articles | 2015
    2015, 'Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM).', Journal of Clinical Oncology, 33, pp. 9073 - 9073, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9073
    Journal articles | 2014
    Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY C; Joshua AM; Chi KN, 2014, 'A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer', Prostate, 74, pp. 1544 - 1550, http://dx.doi.org/10.1002/pros.22872
    Journal articles | 2014
    Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; De Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B, 2014, 'Enzalutamide in metastatic prostate cancer before chemotherapy', New England Journal of Medicine, 371, pp. 424 - 433, http://dx.doi.org/10.1056/NEJMoa1405095
    Journal articles | 2014
    Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK, 2014, 'Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial', JAMA, 311, pp. 2397 - 2405, http://dx.doi.org/10.1001/jama.2014.6096
    Journal articles | 2014
    Gedye C; Hogg D; Butler M; Joshua AM, 2014, 'New treatments for metastatic melanoma', CMAJ. Canadian Medical Association Journal, 186, pp. 754 - 760, http://dx.doi.org/10.1503/cmaj.130989
    Journal articles | 2014
    Joshua AM; Zannella VE; Downes MR; Bowes B; Hersey K; Koritzinsky M; Schwab M; Hofmann U; Evans A; Van Der Kwast T; Trachtenberg J; Finelli A; Fleshner N; Sweet J; Pollak M, 2014, 'A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer', Prostate Cancer and Prostatic Diseases, 17, pp. 252 - 258, http://dx.doi.org/10.1038/pcan.2014.20
    Journal articles | 2014
    Lebowitz-Amit R; Mete O; Asa SL; Ezzat S; Joshua AM, 2014, 'Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: A case report and literature review', Endocrine Practice, 20, http://dx.doi.org/10.4158/EP14093.CR
    Journal articles | 2014
    Leibowitz-Amit R; Alimohamed N; Vera-Badillo FE; Seah JA; Templeton AJ; Knox JJ; Tannock IF; Sridhar SS; Joshua AM, 2014, 'Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone', Prostate, 74, pp. 1462 - 1464, http://dx.doi.org/10.1002/pros.22861
    Journal articles | 2014
    Leibowitz-Amit R; Seah JA; Atenafu EG; Templeton AJ; Vera-Badillo FE; Alimohamed N; Knox JJ; Tannock IF; Sridhar SS; Joshua AM, 2014, 'Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole', European Journal of Cancer, http://dx.doi.org/10.1016/j.ejca.2014.06.004
    Journal articles | 2014
    Leibowitz-Amit R; Templeton AJ; Omlin A; Pezaro C; Atenafu EG; Keizman D; Vera-Badillo F; Seah JA; Attard G; Knox JJ; Sridhar SS; Tannock IF; De Bono JS; Joshua AM, 2014, 'Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer', Annals of Oncology, 25, pp. 657 - 662, http://dx.doi.org/10.1093/annonc/mdt581
    Journal articles | 2014
    Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A, 2014, 'Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial', The Lancet, 384, pp. 1109 - 1117, http://dx.doi.org/10.1016/S0140-6736(14)60958-2
    Journal articles | 2014
    2014, 'A Phase Ii Study (Nct01883323) Evaluating the Infusion of Autologous Tumor-Infiltrating Lymphocytes (Til) and Low-Dose Interleukin-2 (Il-2) Therapy Following Non-Myeloablative Lymphodepletion Using Cyclophosphamide and Fludarabine in Patients with Metastatic Melanoma', Annals of Oncology, 25, pp. iv391 - iv391, http://dx.doi.org/10.1093/annonc/mdu344.44
    Journal articles | 2014
    2014, 'A feasibility trial of geriatric assessment and management for older cancer patients', Journal of Geriatric Oncology, 5, pp. S47 - S48, http://dx.doi.org/10.1016/j.jgo.2014.09.080
    Journal articles | 2014
    2014, 'Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).', Journal of Clinical Oncology, 32, pp. LBA9000 - LBA9000, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.lba9000
    Journal articles | 2014
    2014, 'Fine Needle Biopsies are Feasible As a Minimally Invasive Means for Targeted Next Generation Sequencing in Advanced Solid Tumors', Annals of Oncology, 25, pp. iv558 - iv558, http://dx.doi.org/10.1093/annonc/mdu358.43
    Journal articles | 2014
    2014, 'MP60-12 MULTI-INSTITUTIONAL QUALITY CARE INITIATIVE TO IMPROVE THE CARE OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER', Journal of Urology, 191, http://dx.doi.org/10.1016/j.juro.2014.02.1766
    Journal articles | 2014
    2014, 'Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)', Journal for immunotherapy of cancer, 2, pp. P103 - P103, http://dx.doi.org/10.1186/2051-1426-2-s3-p103
    Journal articles | 2014
    2014, 'Traitement par anticorps anti-PD-1 : pembrolizumab (MK-3475) chez 411 patients (pts) atteints de mélanome métastatique', Annales de Dermatologie et de Vénéréologie, 141, pp. S258 - S259, http://dx.doi.org/10.1016/j.annder.2014.09.084
    Journal articles | 2013
    Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph RW; Weber JS; Dronca R; Gangadhar TC; Patnaik A; Zarour H; Joshua AM; Gergich K; Elassaiss-Schaap J; Algazi A; Mateus C; Boasberg P; Tumeh PC; Chmielowski B; Ebbinghaus SW; Li XN; Kang SP; Ribas A, 2013, 'Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma', New England Journal of Medicine, 369, pp. 134 - 144, http://dx.doi.org/10.1056/NEJMoa1305133
    Journal articles | 2013
    Leibowitz-Amit R; Joshua AM, 2013, 'The changing landscape in metastatic castration-resistant prostate cancer', Current Opinion in Supportive and Palliative Care, 7, pp. 243 - 248, http://dx.doi.org/10.1097/SPC.0b013e328362ffef
    Journal articles | 2013
    Lun G; Atenafu EG; Knox JJ; Sridhar SS; Tannock IF; Joshua AM, 2013, 'Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medication: A pilot project at a canadian cancer center', Clinical Genitourinary Cancer, 11, http://dx.doi.org/10.1016/j.clgc.2013.04.008
    Journal articles | 2013
    Niraula S; Pond G; de Wit R; Eisenberger M; Tannock IF; Joshua AM, 2013, 'Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study', Journal of the Canadian Urological Association, 7, http://dx.doi.org/10.5489/cuaj.267
    Journal articles | 2013
    Pra AD; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; Van Der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG, 2013, 'TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: Implications for fusion status anddsb repair', Clinical Cancer Research, 19, pp. 5202 - 5209, http://dx.doi.org/10.1158/1078-0432.CCR-13-1049
    Journal articles | 2013
    Templeton AJ; Vera-Badillo FE; Wang L; Attalla M; De Gouveia P; Leibowitz-Amit R; Knox JJ; Moore M; Sridhar SS; Joshua AM; Pond GR; Amir E; Tannock IF, 2013, 'Translating clinical trials to clinical practice: Outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials', Annals of Oncology, 24, pp. 2972 - 2977, http://dx.doi.org/10.1093/annonc/mdt397
    Journal articles | 2013
    Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ, 2013, 'PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade', Modern Pathology, 26, pp. 435 - 447, http://dx.doi.org/10.1038/modpathol.2012.162
    Journal articles | 2013
    2013, 'A prospective study examining PROs and other geriatric outcomes in older adults with prostate cancer undergoing chemotherapy.', Journal of Clinical Oncology, 31, pp. 9555 - 9555, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9555
    Journal articles | 2013
    2013, 'Abiraterone in metastatic prostate cancer without previous chemotherapy', New England Journal of Medicine, 368, pp. 138 - 148, http://dx.doi.org/10.1056/NEJMoa1209096
    Journal articles | 2013
    2013, 'Abstracts from the 33rd Annual Scientific Meeting of the Canadian Geriatrics Society Toronto, April 2013', Canadian Geriatrics Journal, 16, pp. 66 - 103, http://dx.doi.org/10.5770/cgj.16.85
    Journal articles | 2013
    2013, 'Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.', Journal of Clinical Oncology, 31, pp. 9009 - 9009, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9009
    Journal articles | 2013
    2013, 'Development of an adoptive cell therapy protocol with tumor-infiltrating lymphocytes and intermediate-dose interleukin-2 therapy', Journal for immunotherapy of cancer, 1, pp. P25 - P25, http://dx.doi.org/10.1186/2051-1426-1-s1-p25
    Journal articles | 2013
    2013, 'Does the hurria/CARG tool or VES-13 predict grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer?', Journal of Geriatric Oncology, 4, pp. S37 - S37, http://dx.doi.org/10.1016/j.jgo.2013.09.031
    Journal articles | 2013
    2013, 'Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma.', Journal of Clinical Oncology, 31, pp. 5070 - 5070, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5070
    Journal articles | 2013
    2013, 'Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)', CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 7, pp. E797 - E811, http://dx.doi.org/10.5489/cuaj.1794
    Journal articles | 2013
    2013, 'Metformin use and all-cause and prostate-cancer-specific mortality among diabetic men.', Journal of Clinical Oncology, 31, pp. 5007 - 5007, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5007
    Journal articles | 2013
    2013, 'NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).', Journal of Clinical Oncology, 31, pp. 5042 - 5042, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5042
    Journal articles | 2013
    2013, 'Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC).', Journal of Clinical Oncology, 31, pp. 5058 - 5058, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5058
    Journal articles | 2013
    2013, 'Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).', Journal of Clinical Oncology, 31, pp. CRA9003 - CRA9003, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.cra9003
    Journal articles | 2013
    2013, 'Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).', Journal of Clinical Oncology, 31, pp. CRA9003 - CRA9003, http://dx.doi.org/10.1200/jco.2013.31.18_suppl.cra9003
    Journal articles | 2013
    2013, 'Treatment of octogenarians with castration-resistant prostatecancer with abiraterone and docetaxel', Journal of Geriatric Oncology, 4, pp. S34 - S34, http://dx.doi.org/10.1016/j.jgo.2013.09.025
    Journal articles | 2012
    Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM, 2012, 'Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers', BJU International, 110, pp. 840 - 845, http://dx.doi.org/10.1111/j.1464-410X.2011.10922.x
    Journal articles | 2012
    Fraser M; Zhao H; Luoto KR; Lundin C; Coackley C; Chan N; Joshua AM; Bismar TA; Evans A; Helleday T; Bristow RG, 2012, 'PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: Implications for radiotherapy and chemotherapy', Clinical Cancer Research, 18, pp. 1015 - 1027, http://dx.doi.org/10.1158/1078-0432.CCR-11-2189
    Journal articles | 2012
    Joshua AM, 2012, 'Melanoma prevention: Are we doing enough? A Canadian perspective', Current Oncology, 19, http://dx.doi.org/10.3747/co.19.1222
    Journal articles | 2012
    Morin E; Mete O; Wasserman JD; Joshua AM; Asa SL; Ezzat S, 2012, 'Carney complex with adrenal cortical carcinoma', Journal of Clinical Endocrinology and Metabolism, 97, http://dx.doi.org/10.1210/jc.2011-2321
    Journal articles | 2012
    Niraula S; Chi K; Joshua AM, 2012, 'Beyond Castration-Defining Future Directions in the Hormonal Treatment of Prostate Cancer', Hormones and Cancer, 3, pp. 3 - 13, http://dx.doi.org/10.1007/s12672-011-0096-0
    Journal articles | 2012
    2012, 'A Randomized Phase II Study of OGX-427 Plus Prednisone (P) Vs. P Alone in Patients (PTS) with Metastatic Castration Resistant Prostate Cancer (CRPC)', Annals of Oncology, 23, pp. ix297 - ix297, http://dx.doi.org/10.1016/s0923-7534(20)33525-0
    Journal articles | 2012
    2012, 'A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.', Journal of Clinical Oncology, 30, pp. e15118 - e15118, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15118
    Journal articles | 2012
    2012, 'A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC).', Journal of Clinical Oncology, 30, pp. 4514 - 4514, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4514
    Journal articles | 2012
    2012, 'A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer.', Journal of Clinical Oncology, 30, pp. TPS4695 - TPS4695, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps4695
    Journal articles | 2012
    2012, 'Abstract A15: A phase 2 study of neoadjuvant metformin in prostatic carcinoma', Cancer Research, 72, pp. A15 - A15, http://dx.doi.org/10.1158/1538-7445.prca2012-a15
    Journal articles | 2012
    2012, 'Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy', NEW ENGLAND JOURNAL OF MEDICINE, 367, pp. 1187 - 1197, http://dx.doi.org/10.1056/NEJMoa1207506
    Journal articles | 2012
    2012, 'Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions', Current Oncology, 19, pp. 22 - 31, http://dx.doi.org/10.3747/co.19.1281
    Journal articles | 2011
    Joshua AM; Shen E; Yoshimoto M; Marrano P; Zielenska M; Evans AJ; Van Der Kwast T; Squire JA, 2011, 'Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies', Prostate, 71, pp. 778 - 790, http://dx.doi.org/10.1002/pros.21294
    Journal articles | 2011
    Squire JA; Park PC; Yoshimoto M; Alami J; Williams JL; Evans A; Joshua AM, 2011, 'Prostate Cancer as a Model System for Genetic Diversity in Tumors', Advances in Cancer Research, 112, pp. 183 - 216, http://dx.doi.org/10.1016/B978-0-12-387688-1.00007-7
    Journal articles | 2011
    2011, '133 EVALUATION OF PTEN AND TMPRSS2-ERG ABNORMALITIES IN PROSTATE CANCER BY FISH AND IMMUNOHISTOCHEMISTRY TO ADDRESS INTRA- AND INTER- TISSUE HETEROGENEITY AND DISEASE PROGRESSION', Journal of Urology, 185, http://dx.doi.org/10.1016/j.juro.2011.02.200
    Journal articles | 2010
    Chung C; Dawson LA; Joshua AM; Brade AM, 2010, 'Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: Sunitinib and sorafenib', Anti-Cancer Drugs, 21, pp. 206 - 209, http://dx.doi.org/10.1097/CAD.0b013e328333d679
    Journal articles | 2010
    Nguyen LT; Yen PH; Nie J; Liadis N; Ghazarian D; Al-Habeeb A; Easson A; Leong W; Lipa J; McCready D; Reedijk M; Hogg D; Joshua AM; Quirt I; Messner H; Shaw P; Crump M; Sharon E; Ohashi PS, 2010, 'Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)', PLoS ONE, 5, http://dx.doi.org/10.1371/journal.pone.0013940
    Journal articles | 2010
    Sahi C; Knox JJ; Clemons M; Joshua AM; Broom R, 2010, 'Renal cell carcinoma bone metastases: Clinical advances', Therapeutic Advances in Medical Oncology, 2, pp. 75 - 83, http://dx.doi.org/10.1177/1758834009358417
    Journal articles | 2009
    Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ, 2009, 'Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma', Journal of Clinical Endocrinology and Metabolism, 94, pp. 5 - 9, http://dx.doi.org/10.1210/jc.2008-1836
    Journal articles | 2009
    Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB, 2009, 'Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer', Journal of Clinical Oncology, 27, pp. 6229 - 6236, http://dx.doi.org/10.1200/JCO.2009.22.3370
    Journal articles | 2009
    2009, 'Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies', Journal of Clinical Oncology, 27, pp. 11107 - 11107, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.11107
    Journal articles | 2008
    Joshua AM; Boutros PC, 2008, 'Web-based resources for clinical bioinformatics.', Methods in molecular medicine, 141, pp. 309 - 329, http://dx.doi.org/10.1007/978-1-60327-148-6_17
    Journal articles | 2008
    Joshua AM; Evans A; Van der Kwast T; Zielenska M; Meeker AK; Chinnaiyan A; Squire JA, 2008, 'Prostatic preneoplasia and beyond', Biochimica et Biophysica Acta - Reviews on Cancer, 1785, pp. 156 - 181, http://dx.doi.org/10.1016/j.bbcan.2007.12.001
    Journal articles | 2008
    Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA, 2008, 'Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome', Modern Pathology, 21, pp. 1451 - 1460, http://dx.doi.org/10.1038/modpathol.2008.96
    Journal articles | 2007
    Joshua AM; Vukovic B; Braude I; Hussein S; Zielenska M; Srigley J; Evans A; Squire JA, 2007, 'Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer', Neoplasia, 9, pp. 81 - 89, http://dx.doi.org/10.1593/neo.06745
    Journal articles | 2007
    2007, '654: Telomere Length Analysis of High-Grade Prostatic Intrapeithelial Neoplasia and Surrounding Stroma Predicts Outcome to Prostate Cancer', Journal of Urology, 177, pp. 220 - 220, http://dx.doi.org/10.1016/s0022-5347(18)30894-2
    Journal articles | 2006
    Dalla-Torre CA; Yoshimoto M; Lee CH; Joshua AM; de Toledo SR C; Petrilli AS; Andrade JA D; Chilton-MacNeill S; Zielenska M; Squire JA, 2006, 'Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma', BMC Cancer, 6, http://dx.doi.org/10.1186/1471-2407-6-237
    Journal articles | 2006
    Nordman IC; Iyer S; Joshua AM; Clarke SJ, 2006, 'Advances in the adjuvant treatment of colorectal cancer', ANZ Journal of Surgery, 76, pp. 373 - 380, http://dx.doi.org/10.1111/j.1445-2197.2006.03726.x
    Journal articles | 2006
    Yoshimoto M; Cutz JC; Nuin PA S; Joshua AM; Bayani J; Evans AJ; Zielenska M; Squire JA, 2006, 'Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias', Cancer Genetics and Cytogenetics, 169, pp. 128 - 137, http://dx.doi.org/10.1016/j.cancergencyto.2006.04.003
    Journal articles | 2006
    Yoshimoto M; Joshua AM; Chilton-MacNeill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA, 2006, 'Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement', Neoplasia, 8, pp. 465 - 469, http://dx.doi.org/10.1593/neo.06283
    Journal articles | 2006
    2006, 'Detection of novel variant TMPRSS2 /ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer', Journal of Clinical Oncology, 24, pp. 10029 - 10029, http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10029
    Journal articles | 2006
    2006, 'Telomere dysfunction in prostatic carcinogenesis', Journal of Clinical Oncology, 24, pp. 10021 - 10021, http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10021
    Journal articles | 2005
    Joshua AM; Adams D; McKenzie P; Solomon M; Clarke SJ, 2005, 'Small blue cell tumors of the rectum: CASE 2. Small-cell carcinoma of the rectum', Journal of Clinical Oncology, 23, pp. 912 - 913, http://dx.doi.org/10.1200/JCO.2005.03.094
    Journal articles | 2005
    Joshua AM; Boyer MJ; Subramanian R; Clarke SJ, 2005, 'Smoking reduction does work: Resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years', Respirology, 10, pp. 233 - 238, http://dx.doi.org/10.1111/j.1440-1843.2005.00672.x
    Journal articles | 2005
    Joshua AM; Celermajer DS; Stockler MR, 2005, 'Beauty is in the eye of the examiner: Reaching agreement about physical signs and their value', Internal Medicine Journal, 35, pp. 178 - 187, http://dx.doi.org/10.1111/j.1445-5994.2004.00795.x
    Journal articles | 2005
    Joshua AM; Cotroneo A; Clarke S, 2005, 'Humor and oncology', Journal of Clinical Oncology, 23, pp. 645 - 648, http://dx.doi.org/10.1200/JCO.2005.09.064
    Journal articles | 2005
    Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer M, 2005, 'Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer', Internal Medicine Journal, 35, pp. 468 - 472, http://dx.doi.org/10.1111/j.1445-5994.2005.00883.x
    Journal articles | 2005
    Millward MJ; Joshua A; Kefford R; Aamdal S; Thomson D; Hersey P; Toner G; Lynch K, 2005, 'Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma', Investigational New Drugs, 23, pp. 253 - 256, http://dx.doi.org/10.1007/s10637-005-6734-z
    Journal articles | 2005
    Vardy J; Joshua AM; Clarke SJ; Yarrow PM; Lin BP C, 2005, 'Small blue cell tumors of the rectum: CASE 1. Erwing's sarcoma of the rectum', Journal of Clinical Oncology, 23, pp. 910 - 912, http://dx.doi.org/10.1200/JCO.2005.03.096
    Journal articles | 2005
    2005, 'Retrospective review of pemetrexed with or without platinum in malignant mesothelioma: The Australian ‘Special Access Scheme’ experience', Asia-Pacific Journal of Clinical Oncology, 1, pp. 47 - 52, http://dx.doi.org/10.1111/j.1743-7563.2005.00006.x
    Journal articles | 2005
    2005, 'Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC)', Journal of Clinical Oncology, 23, pp. 4713 - 4713, http://dx.doi.org/10.1200/jco.2005.23.16_suppl.4713
    Journal articles | 2004
    Joshua AM; Carter JR; Beale P, 2004, 'The use of taxanes in choriocarcinoma; a case report and review of the literature', Gynecologic Oncology, 94, pp. 581 - 583, http://dx.doi.org/10.1016/j.ygyno.2004.05.036
    Journal articles | 2004
    Joshua AM; Stockler MR; Boyer MJ, 2004, 'Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma [1]', Internal Medicine Journal, 34, pp. 70 - 71, http://dx.doi.org/10.1111/j.1444-0903.2004.00514.x
    Journal articles | 2004
    2004, 'An Australian experience of pemetrexed in malignant mesothelioma (MM)', Journal of Clinical Oncology, 22, pp. 7285 - 7285, http://dx.doi.org/10.1200/jco.2004.22.14_suppl.7285
    Journal articles | 2004
    2004, 'An Australian experience of pemetrexed in malignant mesothelioma (MM)', Journal of Clinical Oncology, 22, pp. 7285 - 7285, http://dx.doi.org/10.1200/jco.2004.22.90140.7285
    Journal articles | 1997
    Bennett S; Joshua A; Russell PJ, 1997, 'Reliable method of isolating transfected clones from the LNCaP human prostatic cell line', BioTechniques, 23, pp. 66 - 70, http://dx.doi.org/10.2144/97231bm13
    Journal articles | 1997
    Bennett S; Unknown ; Russell PJ, 1997, 'Isolation of transfected clones from the LNCaP human prostatic cell line', BioTechniques, pp. 66 - 68
  • Conference Abstracts | 2022
    2022, 'A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 95 - 95, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.095
    Conference Abstracts | 2022
    2022, 'Abstract 665: Correlation between a CTLA-4 single nucleotide polymorphism and high response to anti-PD1/PDL1 immunotherapy in advanced non small cell lung cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. 665 - 665, http://dx.doi.org/10.1158/1538-7445.am2022-665
    Conference Abstracts | 2022
    2022, 'BRAF inhibition and the spectrum of Granulomatous Reactions', in AUSTRALASIAN JOURNAL OF DERMATOLOGY, WILEY, Vol. 63, pp. 106 - 106, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000788396100260&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    2022, 'Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps9610
    Conference Abstracts | 2022
    2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5027 - 5027, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5027
    Conference Papers | 2022
    2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of Lu-177-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301444&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    2022, 'Descriptive analysis of bleomycin induced lung injury in a cohort of patients with germ cell tumours and Hodgkin's lymphoma', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 37 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000879941200033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    2022, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.TPS205
    Conference Papers | 2022
    2022, 'Impact of Covid-19 on early phase clinical trials recruitment and treatment in a major metropolitan phase 1 unit', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 33 - 34, http://dx.doi.org/10.1111/ajco.13856
    Conference Abstracts | 2022
    2022, 'KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)-naive patients with metastatic castration-resistant prostate cancer (mCRPC)', in EUROPEAN UROLOGY, ELSEVIER, Vol. 81, pp. S789 - S790, http://dx.doi.org/10.1016/s0302-2838(22)00608-x
    Conference Abstracts | 2022
    2022, 'KEYNOTE-365 cohort I: Phase 1b/2 study of pembrolizumab combined with platinum-containing chemotherapy and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS218 - TPS218, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.tps218
    Conference Abstracts | 2022
    2022, 'KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab + lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS215 - TPS215, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.tps215
    Conference Abstracts | 2022
    2022, 'KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab + vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS204 - TPS204, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.tps204
    Conference Abstracts | 2022
    2022, 'Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.154
    Conference Abstracts | 2022
    2022, 'PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5017 - 5017, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5017
    Conference Abstracts | 2022
    2022, 'PRINCE: Phase I trial of Lu-177-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301433&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    2022, 'PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.010
    Conference Abstracts | 2022
    2022, 'Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 118 - 118, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.118
    Conference Abstracts | 2022
    2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1(77)LuPSMA-617 and NOX66 (LuPIN).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.166
    Conference Abstracts | 2022
    2022, 'Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.224
    Conference Abstracts | 2022
    2022, 'Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 4537 - 4537, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.4537
    Conference Abstracts | 2022
    2022, 'Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301357&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    2022, 'Telehealth maintains access to early phase clinical trials during the Covid-19 pandemic', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 154 - 155, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000871956500233&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    2022, 'TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5000 - 5000, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5000
    Conference Abstracts | 2022
    2022, 'TheraP: Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301419&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Preprints | 2022
    2022, A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers, , http://dx.doi.org/10.1101/2022.06.30.22277092
    Preprints | 2022
    2022, Extracellular vesicles from biological fluids as potential biomarkers for prostate cancer, , http://dx.doi.org/10.21203/rs.3.rs-1948091/v1
    Conference Papers | 2022
    Sacco JJ; Orloff MM; Patel SP; Conway M; Lim L-A; Fog LS; Sia D; McKenzie J; Mckay D; O'day R; Isaacs T; Shoushtari AN; Sullivan RJ; Kin S; Gwadry-Sridhar FH; Joshua AM; Carvajal RD, 2022, 'Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680305166&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2021
    2021, '177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.6
    Conference Abstracts | 2021
    2021, 'A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.114
    Conference Papers | 2021
    2021, 'Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma', in Cancer Research, American Association for Cancer Research (AACR), pp. CT002 - CT002, presented at Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA, http://dx.doi.org/10.1158/1538-7445.am2021-ct002
    Conference Abstracts | 2021
    2021, 'Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S666 - S667, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1148
    Conference Papers | 2021
    2021, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 48 - 49, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000705028800031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2021
    2021, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS177
    Conference Abstracts | 2021
    2021, 'Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.103
    Conference Abstracts | 2021
    2021, 'Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S642 - S643, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1109
    Conference Papers | 2021
    2021, 'Lu-177-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, ELECTR NETWORK, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), ELECTR NETWORK, 12 June 2021 - 15 June 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713713600793&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2021
    2021, 'MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion', in ANNALS OF ONCOLOGY, ELSEVIER, pp. S657 - U246, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000700527701084&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2021
    2021, 'PRINCE: Interim analysis of the phase Ib study of Lu-177-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S626 - S627, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1090
    Conference Papers | 2021
    2021, 'The influence of concurrent lipid modifying medications in men receiving docetaxel or cabazitaxel for mCRPC - A meta-analysis of the FIRSTANA, PROSELICA, TAX-327 and TROPIC studies', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 68 - 69, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000705028800065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2021
    2021, 'UNISON - nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1-Nivolumab monotherapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.325
    Conference Abstracts | 2021
    2021, 'UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naive prostate cancer (mHNPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS180
    Preprints | 2021
    2021, A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program, , http://dx.doi.org/10.21203/rs.3.rs-254137/v1
    Conference Abstracts | 2020
    2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368301329&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2020
    2020, 'KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 38, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, http://dx.doi.org/10.1016/s2666-1683(20)33163-3
    Conference Abstracts | 2020
    2020, 'KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. 103 - 103, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.103
    Conference Abstracts | 2020
    2020, 'MP67-12 ANTI-ANDROGENS AND CABAZITAXEL IN DEFINING COMPLETE RESPONSE IN PROSTATECTOMY (ACDC TRIAL) (ACDC-RP)', in Journal of Urology, Ovid Technologies (Wolters Kluwer Health), Vol. 203, http://dx.doi.org/10.1097/ju.0000000000000947.012
    Conference Posters | 2020
    2020, 'P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma', Vol. 8, pp. A10.2 - A11, presented at 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): late breaking abstracts, http://dx.doi.org/10.1136/lba2019.16
    Conference Papers | 2020
    2020, 'PHASE 1/2 STUDY USING ENB-003, A FIRST-IN-CLASS SELECTIVE ETBRI, IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED REFRACTORY SOLID TUMORS', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A480 - A481, http://dx.doi.org/10.1136/jitc-2020-SITC2020.0803
    Conference Abstracts | 2020
    2020, 'Phase I/II trial assessing hydroxychloroquine and itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-01).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302474&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2020
    2020, 'Phase I/II trial assessing hydroxychloroquine and itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-01).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. 6049 - 6049, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6049
    Conference Papers | 2020
    2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900189&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2020
    2020, 'Targeting lysosomal homeostasis in ovarian cancer through drug repurposing', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-3401
    Conference Papers | 2020
    2020, 'The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900143&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2020
    2020, 'TheraP: A randomised phase II trial of Lu-177-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302345&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2020
    2020, 'Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900148&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2020
    2020, 'UNISON: Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 38, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900071&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2020
    2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Preprints | 2020
    2020, Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment, , http://dx.doi.org/10.1101/2020.04.08.032565
    Conference Papers | 2019
    2019, 'Abstract 3141: The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma', in Clinical Research (Excluding Clinical Trials), American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-3141
    Conference Abstracts | 2019
    2019, 'FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.8_suppl.TPS42
    Conference Abstracts | 2019
    2019, 'High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.TPS5095
    Conference Abstracts | 2019
    2019, 'Interim results of a Phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and NOX66 in men with mCRPC post androgen signalling inhibition and 2 lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CA, Anaheim, Vol. 60, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CA, Anaheim, 22 June 2019 - 25 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473116800464&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.171
    Conference Abstracts | 2019
    2019, 'Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.170
    Conference Papers | 2019
    2019, 'List of Poster Abstracts', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 31 - 32, http://dx.doi.org/10.1111/ajco.13228
    Conference Abstracts | 2019
    2019, 'Lu-177-PSMA-617 as monotherapy or in combination with NOX66 for the treatment of men with late-stage metastatic castrate resistant prostate cancer (mCRPC): An exploratory analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 115 - 115, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400147&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.6550
    Conference Abstracts | 2019
    2019, 'Modulation of plasma lipidomic signature in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.TPS331
    Conference Papers | 2019
    2019, 'Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (Ribociclib) in High-Risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (Leep Study)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 64 - 64, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200064&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'Preoperative trial of neoadjuvant abiraterone plus or minus cabazitaxel: Early results.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.98
    Conference Abstracts | 2019
    2019, 'Rapid modulation of PSMA expression by ADT: Serial PSMA PET in men commencing androgen blockade.', in RADIOTHERAPY AND ONCOLOGY, ELSEVIER IRELAND LTD, ITALY, Milan, Vol. 133, pp. S445 - S446, presented at 38th Annual Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO), ITALY, Milan, 26 April 2019 - 30 April 2019, http://dx.doi.org/10.1016/S0167-8140(19)31267-8
    Conference Papers | 2019
    2019, 'The Australian Exceptional Responders Program: A national collaboration', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295505242&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    2019, 'The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.3136
    Conference Abstracts | 2019
    2019, 'The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3141
    Conference Abstracts | 2019
    2019, 'Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000487345804179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2018
    Carvajal RD; Piperno-Neumann S; Kapiteijn E; Chapman PB; Frank S; Joshua AM; Piulats JM; Wolter P; Cocquyt V; Chmielowski B; Evans TR J; Gastaud L; Linette G; Berking C; Schachter J; Rodrigues MJ; Shoushtari AN; Clemett D; Ghiorghiu D; Mariani G; Spratt S; Lovick S; Barker P; Kilgour E; Lai Z; Schwartz GK; Nathan P, 2018, 'Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)', in Journal of Clinical Oncology, pp. 1232 - 1239, http://dx.doi.org/10.1200/JCO.2017.74.1090
    Conference Papers | 2018
    2018, 'A phase I study of Lu-177-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS5088
    Conference Abstracts | 2018
    2018, 'Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Vol. 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.3063
    Conference Papers | 2018
    2018, 'Modulation of PSMA expression by Androgen deprivation therapy (ADT): Serial PSMA PET in men with hormone sensitive, and castrate resistant prostate cancer commencing androgen blockade', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, PA, Philadelphia, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), PA, Philadelphia, 23 June 2018 - 26 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000467489900093&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    2018, 'The cancer molecular screening and therapeutics program (MoST): A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies', in Annals of oncology : official journal of the European Society for Medical Oncology, OXFORD UNIV PRESS, Munich, GERMANY, Vol. 29, pp. viii147, presented at 43rd ESMO Congress (ESMO), Munich, GERMANY, 19 October 2018 - 23 October 2018, http://dx.doi.org/10.1093/annonc/mdy279.434
    Conference Abstracts | 2017
    Kanjanapan Y; Day D; Butler M; Wang L; Joshua AM; Hogg D; Leighl NB; Razak AR A; Hansen AR; Boujos S; Chappell MA; Chow K; Paolo M; Sherwin B; Stayner L-A; Soultani L; Zambrana A; Siu LL; Bedard PL; Spreafico A, 2017, 'Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, Vol. 28, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324001056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2017
    Khoja L; Atenafu E; Joshua AM, 2017, 'Validating prognostic models in metastatic uveal melanoma (MUM), an international rare cancers initiative', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, Vol. 28, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324003103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2017
    Lin FP-Y; Martin C; Kocbek S; Joshua AM; Dear RF-G; Lim E; Chantrill LA; Chin VT; Epstein RJ, 2017, 'Identifying determinants of quality of life in patients undergoing systemic therapy for solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.6596
    Conference Posters | 2017
    2017, 'Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial.', IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.TPS5095
    Conference Posters | 2017
    2017, 'Patterns of failure on Ga PSMA (GaPSMA) and F18 FDG (FDG) PET CT in a prospective phase 2 trial of Lu-177 DKFZ PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC)', IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.2562
    Conference Posters | 2017
    2017, 'The Molecular Screening and Therapeutics (MoST) Program: A precision medicine framework for biomarker-driven signal seeking clinical studies for rare cancers.', IL, Chicago, Vol. 35, presented at 53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 06 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.TPS2621
    Conference Posters | 2016
    Bavi P; Kiehl R; Adeyi O; Mete O; Avila-Casado C; Sharifzad H; Joshua A; Butany J; Roehrl MH, 2016, 'Immune-Related Adverse Events (irAEs) Following CTLA-4 and PD-1/PD-L1 Blockade in Advanced Melanoma: A Comprehensive Rapid Autopsy Study', WA, Seattle, Vol. 29, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000370302500004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2016
    Bavi P; Kiehl R; Adeyi O; Mete O; Avila-Casado C; Sharifzad H; Joshua A; Butany J; Roehrl MH, 2016, 'Immune-Related Adverse Events (irAEs) Following CTLA-4 and PD-1/PD-L1 Blockade in Advanced Melanoma: A Comprehensive Rapid Autopsy Study', WA, Seattle, Vol. 96, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000369270700004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2016
    Bavi P; Sharifzad H; Butany J; Joshua A; Roehrl MH, 2016, 'Our Rapid Research Autopsy Program: A Solid Platform for Next Generation Clinical Trials', WA, Seattle, Vol. 29, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000370302500003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2016
    Bavi P; Sharifzad H; Butany J; Joshua A; Roehrl MH, 2016, 'Our Rapid Research Autopsy Program: A Solid Platform for Next Generation Clinical Trials', WA, Seattle, Vol. 96, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000369270700003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2016
    Bavi P; Sharifzad H; Yang Q; Oldfield L; Joshua A; Butany J; Roehrl MH, 2016, 'Unique Insights into Cardiac Metastases and Tumor Biology from a Cancer Center's Rapid Research Autopsy Program', WA, Seattle, Vol. 29, pp. 81A - 81A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000370302500318&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2016
    Bavi P; Sharifzad H; Yang Q; Oldfield L; Joshua A; Butany J; Roehrl MH, 2016, 'Unique Insights into Cardiac Metastases and Tumor Biology from a Cancer Center's Rapid Research Autopsy Program', WA, Seattle, Vol. 96, pp. 81A - 81A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000369270700318&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2016
    Corfield J; Crozier J; Joshua A; Bolton D; Lawrentschuk N, 2016, 'Understanding the role of new systemic agents in the treatment of prostate cancer', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Melbourne, pp. 12 - 12, presented at 17th Asia-Pacific Prostate Cancer Conference, AUSTRALIA, Melbourne, 31 August 2016 - 03 September 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000381708200019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2016
    Manders P; Joshua AM; Kefford R; Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Hwu W-J; Weber JS; Gangadhar TC; Joseph R; Dronca R; Patnaik A; Zarour H; Hersey P; Li XN; Diede SJ; Ebbinghaus S; Hodi FS, 2016, 'THREE-YEAR OVERALL SURVIVAL FOR PATIENTS WITH ADVANCED MELANOMA TREATED WITH PEMBROLIZUMAB IN KEYNOTE-001', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 47 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380005100012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2016
    Puts M; Sattar S; McWatters K; Lee K; Kulik M; Macdonald ME; Jang RW-J; Amir E; Krzyzanowska MK; Leighl NB; Fitch M; Joshua AM; Warde PR; Tourangeau A; Alibhai SM H, 2016, 'What is the role of comorbidity, frailty, and functional status in the decision-making process for older adults with cancer and their family members, oncologists, and family physician?', CA, San Francisco, Vol. 34, presented at Cancer Survivorship Symposium on Advancing Care and Research, CA, San Francisco, 15 January 2016 - 16 January 2016, http://dx.doi.org/10.1200/jco.2016.34.3_suppl.92
    Conference Posters | 2016
    Smith AD; Truong M; Bristow R; Wouters B; Milosevic MF; Joshua AM, 2016, 'The utility of serum CA9 in prognostication in prostate cancer', CA, San Francisco, Vol. 34, presented at Genitourinary Cancers Symposium, CA, San Francisco, 07 January 2016 - 09 January 2016, http://dx.doi.org/10.1200/jco.2016.34.2_suppl.309
    Conference Posters | 2016
    Todenhfer T; Azad A; Stewart C; Gao J; Eigl BJ; Black PC; Joshua AM; Chi KN, 2016, 'Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI).', CA, San Francisco, Vol. 34, presented at Genitourinary Cancers Symposium, CA, San Francisco, 07 January 2016 - 09 January 2016, http://dx.doi.org/10.1200/jco.2016.34.2_suppl.223
    Conference Posters | 2016
    2016, 'A feasibility trial of geriatric assessment and integrated care plan for older cancer patients.', IL, Chicago, Vol. 34, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.10054
    Conference Papers | 2016
    2016, 'Abstract 167: Inferring subclonal relationships between multiple metastases from rapid autopsy of a single melanoma patient', in Cancer Research, American Association for Cancer Research (AACR), pp. 167 - 167, presented at Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA, http://dx.doi.org/10.1158/1538-7445.am2016-167
    Conference Posters | 2016
    2016, 'Development of the Princess Margaret Immune Oncology Prognostic Index (PM-IPI): A novel prognostic score for patients (pts) treated in immune oncology (IO) phase I (P1) trials', IL, Chicago, Vol. 34, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.3058
    Conference Posters | 2016
    2016, 'IDH-1/2mutations and associated oncometabolite 2-hydroxyglutarate (2-HG) in solid tumors.', IL, Chicago, Vol. 34, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e23210
    Conference Papers | 2016
    2016, 'Impact of ipilimumab on metastatic melanoma: Evaluation using patient registry in Canada', in Annals of Oncology, OXFORD UNIV PRESS, pp. vi384, http://dx.doi.org/10.1093/annonc/mdw379.17
    Conference Posters | 2016
    2016, 'Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC)', Copenhagen, DENMARK, Vol. 27, pp. vi249, presented at 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, DENMARK, 07 October 2016 - 11 October 2016, http://dx.doi.org/10.1093/annonc/mdw372.20
    Conference Posters | 2016
    2016, 'Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): a phase II trial in men with castration resistant prostate cancer (mCRPC).', IL, Chicago, Vol. 34, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e16502
    Conference Papers | 2015
    Abi-Saab T; Bavi P; Jiang J; Siva M; Chadwick D; Joshua A; Roehrl M, 2015, 'The Effect of Time Between Patient Death and Tissue Collection on RNA Integrity of Metastatic Tumors', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MA, Boston, pp. 4A - 4A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, MA, Boston, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000348948000002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Abi-Saab T; Bavi P; Jiang J; Siva M; Chadwick D; Joshua A; Roehrl M, 2015, 'The Effect of Time Between Patient Death and Tissue Collection on RNA Integrity of Metastatic Tumors', in MODERN PATHOLOGY, SPRINGERNATURE, Boston, MA, pp. 4A - 4A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349502200002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Al-Faraidy N; Deodhare N; Naert K; Joshua A; Hogg D; Butler M; Kamel-Reid S; Alhabeeb A; Ghazarian D, 2015, 'Molecular Profiling of Common Melanoma Mutations - A Large Cohort Study', in MODERN PATHOLOGY, SPRINGERNATURE, Boston, MA, pp. 510A - 511A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349502203246&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Al-Faraidy N; Deodhare N; Naert K; Joshua A; Hogg D; Butler M; Kamel-Reid S; Alhabeeb A; Ghazarian D, 2015, 'Molecular Profiling of Common Melanoma Mutations A Large Cohort Study', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MA, Boston, pp. 510A - 511A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, MA, Boston, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000348948003549&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2015
    Alibhai SM H; Manokumar T; Aziz S; Rizvi F; Breunis H; Joshua AM, 2015, 'Does frailty affect response to chemotherapy in older men with metastatic castration-resistant prostate cancer?', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036904159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Bavi P; Siva M; Buany J; Joshua A; Roehrl M, 2015, 'A Cancer Center's Large-Scale Rapid (Warm) Autopsy Program: Unique Insights Into Tumor Kinetics and Biology', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MA, Boston, pp. 4A - 4A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, MA, Boston, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000348948000004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Bavi P; Siva M; Butany J; Joshua A; Roehrl M, 2015, 'A Cancer Center's Large-Scale Rapid (Warm) Autopsy Program: Unique Insights Into Tumor Kinetics and Biology', in MODERN PATHOLOGY, SPRINGERNATURE, Boston, MA, pp. 4A - 4A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Boston, MA, 21 March 2015 - 27 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349502200004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Beer TM; Armstrong AJ; Sternberg CN; Higano CS; Rathkopf DE; Loriot Y; Saad F; Joshua AM; De Bono JS; Venner PM; Carles J; Mainwaring PN; Evans CP; Parli T; Mansbach HH; Bhattacharya S; Van Os S; Phung D; Tombal BF, 2015, 'Enzalutamide (ENZA) in men with chemotherapy-Naive metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036901078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2015
    Bruce JP; Danesh A; Winegarden N; Yau P; Virtanen C; Kamel-Reid S; Roehrl MH; Joshua AM; Knox J; Pugh TJ, 2015, 'Exome analysis of an exceptional responder uncovers an activating GNAS mutation that may confer sensitivity to cytotoxic chemotherapy', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-3898
    Conference Papers | 2015
    Daud A; Joshua AM; Ribas A; Robert C; Hodi FS; Wolchok J; Hwu W-J; Weber JS; Gangadhar TC; Joseph R; Dronca R; Patnaik A; Zarour H; Kefford R; Lindia J; Li XN; Ebbinghaus S; Kang SP; Hamid O, 2015, 'A POOLED ANALYSIS OF 655 PATIENTS WITH ADVANCED MELANOMA ENROLLED IN KEYNOTE-001: LONG-TERM EFFICACY OF PEMBROLIZUMAB (MK-3475)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 43 - 43, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357957300008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Presentations | 2015
    Daud A; Ribas A; Robert C; Hodi FS; Wolchok JD; Joshua AM; Hwu W-J; Weber JS; Gangadhar TC; Joseph RW; Dronca RS; Patnaik A; Zarour HM; Kefford R; Lindia JA; Li XN; Ebbinghaus S; Kang SP; Hamid O, 2015, 'Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.', Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036901915&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2015
    Gill B; Khoja L; Li ZJ; Hamilton RJ; Koritzinsky M; Penn L; Abdallah K; Pintilie M; Joshua AM, 2015, 'Project data sphere (PDS) in prostate cancer: A first look including concomitant medication use.', FL, Orlando, Vol. 33, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.204
    Conference Papers | 2015
    Hotte SJ; Joshua AM; Torri V; Macfarlane RJ; Basappa NS; Powers J; Winquist E; Mukherjee S; Gregg RW; Kollmannsberger CK; Finch DL; Xu H; Hausman DF; Seymour L; Eisenhauer EA; Chi KN, 2015, 'IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.279
    Conference Posters | 2015
    Jeganathan S; Zoubeidi A; Gleave M; Wouters BG; Joshua AM, 2015, 'Using functional and chemical genomics to identify mechanisms of Enzalutamide resistance in prostate cancer', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-732
    Conference Posters | 2015
    Joshua AM; Gill B; Khoja L; Pintilie M; Abdallah K, 2015, 'Project Data Sphere: A first look at prostate cancer including concomitant medication use, prognosis, and toxicity.', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5022
    Conference Posters | 2015
    Khoja I; Joshua AM; Wang L; Hogg D; Linh N; Sotov V; Motta V; Scheid L; Gray D; Hirano N; Butler MO, 2015, 'A pilot study of adoptive cell therapy with in vitro educated MART1 T cells in combination with ipilimumab for the treatment of metastatic melanoma', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-CT226
    Conference Posters | 2015
    Khoja L; Kurtz G; Bernstein M; Joshua AM; Hogg D; Zadeh G; Laperriere N; Menard C; Miller B-A; Kongkham PN; Atenafu EG; Butler MO; Chung C, 2015, 'Brain radiosurgery and ipilimumab (Ipi) in melanoma brain metastases (MBM) patients: Does an enhanced immune response induce radionecrosis (RN)?', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036904043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2015
    Kibiro M; Khoja L; Hogg D; Butler MO; Metser U; Atenafu EG; Joshua AM, 2015, 'Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM)', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036901983&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Leibowitz-Amit R; Pintille M; Laird AD; Aftab DT; Berger R; Chi KN; Joshua AM, 2015, 'Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trials', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.196
    Conference Posters | 2015
    McWhirter E; Hamid O; Chmielowski B; Carvajal RD; Jaffray DA; Driscoll B; Shek T; Yeung I; Keller H; McKee TD; Pearce TE; Kroll S; Joshua AM, 2015, 'A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036904887&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Presentations | 2015
    Montgomery B; Joshua A; Gleave M; Fleshner N; Bubley G; True L; Tretiakova M; Wu K; Novotny W; Peterson A; Amelsberg A; Taplin ME, 2015, 'A randomized, open-label, phase 2 study of enzalutamide as neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer', Vol. 51, pp. S473 - S473, presented at European Cancer Congress 2015 / 18th Meeting of the European-Cancer-Organization (ECCO) / 40th Meeting of the European-Society-for-Medical-Oncology (ESMO), AUSTRIA, Vienna, 25 September 2015 - 29 September 2015, http://dx.doi.org/10.1016/S0959-8049(16)31323-5
    Conference Posters | 2015
    Montgomery RB; Antonarakis ES; Hussain M; Fizazi K; Joshua AM; Attard G; Sadar M; Perabo F; Chi KN, 2015, 'A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps5072
    Conference Papers | 2015
    Puts M; Sattar S; McWatters K; Lee K; Amir E; Krzyzanowska MK; Joshua AM; Monette J; Wan-Chow-Wah D; Jang RW-J; Alibhai SM H, 2015, 'A feasibility trial of geriatric assessment and integrated care plan for older cancer patients.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036904893&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Ribas A; Robert C; Hodi FS; Wolchok JD; Joshua AM; Hwu W-J; Weber JS; Zarour HM; Kefford R; Loboda A; Albright A; Kang SP; Ebbinghaus S; Yearley J; Murphy E; Nebozhyn M; Lunceford JK; McClanahan T; Ayers M; Daud A, 2015, 'Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.3001
    Conference Papers | 2015
    Ribas A; Wolchok JD; Robert C; Kefford R; Hamid O; Daud A; Hwu W-J; Weber JS; Joshua AM; Gangadhar TC; Patnaik A; Hersey P; Dronca R; Zarour H; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Hodi FS, 2015, 'UPDATED CLINICAL EFFICACY OF THE ANTI-PD-1 MONOCLONAL ANTIBODY PEMBROLIZUMAB (MK-3475) IN 411 PATIENTS WITH MELANOMA', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, PEOPLES R CHINA, Shanghai, pp. E24 - E24, presented at 7th Annual Asian Oncology Summit / 11th Annual Conference of the Organisation-for-Oncology-and-Translational-Research, PEOPLES R CHINA, Shanghai, 10 April 2015 - 12 April 2015, http://dx.doi.org/10.1016/j.ejca.2015.06.072
    Conference Papers | 2015
    Robert C; Joshua AM; Kefford R; Joseph RW; Wolchok JD; Hodi FS; Hamid O; Weber JS; Gangadhar TC; Dronca RS; Patnaik A; Zarour HM; Hwu W-J; Hersey P; Daud A; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Ribas A, 2015, 'Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036901960&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2015
    Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Wouters B; Tannock IF, 2015, 'Effect of pantoprazole to enhance activity of docetaxel against human tumor xenografts by inhibiting autophagy', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-395
    Conference Posters | 2015
    Wilson MK; Bedard PL; Joshua AM; Mackay H; Butler MO; Dhani NC; Lheureux S; Martin-Lorente C; Rodriguez-Freixinos V; Clarke B; Shaw P; Milea A; Wang L; Kamel-Reid S; Stockley T; Bruce J; Pugh TJ; Oza AM, 2015, 'Molecular profiling and targeted therapy in advanced endometrial cancer.', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5589
    Conference Papers | 2015
    Wolchok JD; Hamid O; Ribas A; Robert C; Kefford R; Hwu W-J; Weber JS; Joshua AM; Gangadhar TC; Dronca RS; Daud A; Patnaik A; Joseph RW; Zarour HM; Li XN; Xue D; Ebbinghaus S; Kang SP; Perrone AM; Hodi FS, 2015, 'Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.3000
    Conference Papers | 2014
    Alimohamed NS; Leibowitz-Amit R; Templeton AJ; Seah J-A; Vera-Badillo FE; Joshua AM; Knox JJ; Tannock I; Sridhar SS, 2014, 'Do special access programs facilitate off-label prescribing? The experience of enzalutamide in prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.6550
    Conference Papers | 2014
    Armstrong AJ; Tombal B; Sternberg CN; Higano CS; Rathkopf DE; Loriot Y; Saad F; Joshua AM; De Bono JS; Venner PM; Caries J; Mainwaring PN; Evans CP; Noonberg SB; Mansbach HH; Bhattacharya S; Perabo F; Phung D; Beer TM, 2014, 'Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5007
    Conference Papers | 2014
    Azad A; Lester R; Leibowitz-Amit R; Joshua AM; Heng DY C; Eigl BJ; Chi KN, 2014, 'Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.29
    Conference Papers | 2014
    Azad A; Lester R; Leibowitz-Amit R; Joshua AM; Heng DY C; Eigl BJ; Chi KN, 2014, 'Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5078
    Conference Papers | 2014
    Beer TM; Armstrong AJ; Sternberg CN; Higano CS; Iversen P; Loriot Y; Rathkopf DE; Bhattacharya S; Carles J; De Bono JS; Evans CP; Joshua AM; Kim C-S; Kimura G; Mainwaring PN; Mansbach HH; Miller K; Noonberg SB; Venner PM; Tombal B, 2014, 'Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.lba1
    Conference Papers | 2014
    Daud A; Hamid O; Robert C; Hodi FS; Wolchok JD; Hwu WJ; Weber JS; Kefford R; Hersey P; Joshua AM; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Gerigich K; Lunceford J; Emacipator K; Dolled-Filhart M; Li X; Kang P; Ebbinghaus S; Ribas A, 2014, 'Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, European Org Res & Treatment Canc, Barcelona, pp. 48 - 49, presented at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SPAIN, European Org Res & Treatment Canc, Barcelona, 18 November 2014 - 21 November 2014, http://dx.doi.org/10.1016/S0959-8049(14)70266-7
    Conference Papers | 2014
    Daud AI; Hamid O; Ribas A; Hodi FS; Hwu W-J; Kefford R; Wolchok J; Hersey P; Weber JS; Joseph R; Gangadhar TC; Dronca RS; Patnaik A; Zarour H; Joshua AM; Gergich K; Wu D; Lunceford JK; Emancipator K; Dolled-Filhart M; Li N; Ebbinghaus S; Kang SP; Robert C, 2014, 'Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-CT104
    Conference Papers | 2014
    Efstathiou E; Deshpande H; George D; Joshua AM; Taplin M-E; Griffin TW; Londhe A; Todd M; Molina A, 2014, 'An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx)', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-CT313
    Conference Papers | 2014
    Hamid O; Robert C; Ribas A; Wolchok JD; Hodi FS; Kefford R; Joshua AM; Hwu W-J; Gangadhar TC; Patnaik A; Hersey P; Weber JS; Joseph RW; Gergich K; Li XN; Chun P; Ebbinghaus S; Kang SP; Daud A, 2014, 'Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-347 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.3000
    Conference Papers | 2014
    Hamilton RJ; Li J; Naini V; San Kheoh T; De Porre P; Molina A; Lelbowitz-Amit R; De Bono JS; Scher HI; Ryan CJ; Chi KN; Joshua AM, 2014, 'Effect of concomitant medication use on outcomes of ties and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.e16045
    Conference Papers | 2014
    Hersey P; Ribas A; Hodi FS; Kefford R; Hamid O; Daud A; Wolchok JD; Hwu W-J; Gangadhar TC; Patnaik A; Joshua AM; Weber J; Dronca R; Zarour H; Gergich K; Li X; Iannone R; Kang SP; Ebbinghaus S; Robert C, 2014, 'EFFICACY AND SAFETY OF THE ANTI-PD-1 MONOCLONAL ANTIBODY MK-3475 IN 411 PATIENTS (pts) WITH MELANOMA', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 48 - 49, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Hodi FS; Ribes A; Daud A; Hamid O; Robert C; Kefford R; Hwu W-J; Gangadhar TC; Joshua AM; Hersey P; Weber JS; Dronca RS; Perrone AM; Gammage L; Mille D; Xue D; Kang SP; Chun P; Ebbinghaus S; Wolchok JD, 2014, 'Evaluation of immune-related response criteria (irRC) in patients (pis) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.3006
    Conference Papers | 2014
    Joseph RW; Elassaiss-Schaap J; Wolchok JD; Joshua AM; Ribas A; Hodi FS; Hamid M; Robert C; Daud A; Hwu W-J; Kefford R; Hersey P; Weber JS; Patnaik A; De Alwis DP; Perrone AM; Kang SP; Ebbinghaus S; Anderson KM; Gangadhar TC, 2014, 'Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.3015
    Conference Papers | 2014
    Joshua AM; Shore ND; Saad F; Chi KN; Olsson CA; Emmenegger U; Scholz MC; Berry WR; Mukherjee S; Winquist E; Haas NB; Hasabou N; Dmuchowski C; Perabo F; Hirmand M; Foley MA; Rathkopf DE, 2014, 'Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5051
    Conference Papers | 2014
    Kefford R; Hamid O; Robert C; Ribas A; Wolchock JD; Hodi FS; Joshua AM; Hwu W-J; Gangadhar TC; Patnaik A; Hersey P; Weber J; Joseph R; Gergich K; Li X; Chun P; Ebbinghaus S; Kang SP; Daud A, 2014, 'Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma', in BRITISH JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL, SCOTLAND, Edinburgh, pp. 44 - 44, presented at 15th World Congress on Cancers of the Skin, SCOTLAND, Edinburgh, 03 September 2014 - 06 September 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342680900098&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Kefford R; Hamid O; Robert C; Ribas A; Wolchock JD; Hodi FS; Joshua AM; Hwu W-J; Gangadhar TC; Patnaik A; Hersey P; Weber J; Joseph R; Gergich K; Li X; Chun P; Ebbinghaus S; Kang SP; Daud A, 2014, 'Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma', in BRITISH JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL, SCOTLAND, Edinburgh, pp. E56 - E56, presented at 15th World Congress on Cancers of the Skin, SCOTLAND, Edinburgh, 03 September 2014 - 06 September 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344006900098&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Kefford R; Ribas A; Hamid O; Robert C; Daud A; Wolchok JD; Joshua AM; Hodi FS; Gangedher TC; Hersey P; Weber JS; Dronca RS; Patnaik A; Zarour HM; Dolled-Filhart M; Lunceford J; Emancipator K; Ebbinghaus S; Rang SP; Hwu W-J, 2014, 'Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.3005
    Conference Papers | 2014
    Khoja L; Kurtz G; Zadeh G; Laperriere N; Menard C; Millar B-A; Bernstein M; Kongkham P; Joshua A; Hogg D; Butler M; Chung C, 2014, 'INCREASED ACUTE RADIATION EFFECT (ARE) WITH IPILUMUMAB AND RADIOSURGERY IN PATIENTS WITH MELANOMA BRAIN METASTASES', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, http://dx.doi.org/10.1093/neuonc/nou240.16
    Conference Papers | 2014
    Leibowitz-Amit R; Atenafu EG; Seah J-A; Templeton AJ; Vera-Badillo FE; Alimohamed NS; Knox JJ; Sridhar SS; Tannock I; Joshua AM, 2014, 'Low-dose abiraterone (abi) with food in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre experience.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5077
    Conference Papers | 2014
    Leibowitz-Amit R; Atenafu EG; Seah J-A; Templeton AJ; Vera-Badillo FE; Solow HL; Knox JJ; Sridhar SS; Tannock I; Joshua AM, 2014, 'Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.61
    Conference Papers | 2014
    Leibowitz-Amit R; Joshua AM; Ezzat S; Bourdeau I; Olney H; Oosting S; Ruether JD; Chin S; Palmieri C; Seah J-A; Assa SL; Krzyzanowska M; Knox JJ, 2014, 'A single-arm, phase II, multicenter trial of sunitinib maleate (SU) in locally advanced or metastatic', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.431
    Conference Papers | 2014
    Leibowitz-Amit R; Joshua AM; Ezzat S; Bourdeau I; Olney H; Oosting S; Seah J-A; Ruether JD; Chin S; Asa SL; Krzyzanowska MK; Knox JJ, 2014, 'A single-arm, phase II, multicenter trial of sunitinib (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Updated interim results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.e15621
    Conference Papers | 2014
    Ribas A; Hodi FS; Kefford R; Hamid O; Daud A; Wolchok JD; Hwu W-J; Gangadhar TC; Patnaik A; Joshua AM; Hersey P; Weber JS; Dronca RS; Zarour HM; Gergich K; Li XN; Lannone R; Kang SP; Ebbinghaus S; Robert C, 2014, 'Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2014.32.18_suppl.lba9000
    Conference Papers | 2014
    Ribes A; Hodi FS; Kefford R; Hamid O; Daud A; Wolchok JD; Hwu W-J; Gangadhar TC; Patnaik A; Joshua AM; Hersey P; Weber JS; Dronca RS; Zarour HM; Gergich K; Li XN; Iannone R; Kang SP; Ebblnghaus S; Robert C, 2014, 'Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358613201964&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2014
    Robert C; Joshua AM; Weber JS; Ribas A; Hodi FS; Kefford RF; Daud A; Wolchok JD; Hwu W-J; Gangadhar TC; Patnaik A; Hersey P; Dronca R; Zarour H; Ge Y; Lindia JA; Giannotti M; Ebbinghaus S; Kang SP; Hamid O, 2014, 'PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 39th ESMO Congress (ESMO), SPAIN, Madrid, 26 September 2014 - 30 September 2014, http://dx.doi.org/10.1093/annonc/mdu438.42
    Conference Papers | 2014
    Seah J-A; Leibowitz-Amit R; Atenafu EG; Alimohamed N; Joshua AM; Knox JJ; Sridhar SS, 2014, 'Evaluation of the neutrophil-lymphocyte ratio (NLR) during neoadjuvant chemotherapy (NC) for muscle-invasive bladder cancer (MIBC) and correlation with pathologic response to treatment', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.351
    Conference Papers | 2014
    Seah J-A; Leibowitz-Amit R; Atenafu EG; Alimohamed N; Joshua AM; Knox JJ; Tannock I; Sridhar SS, 2014, 'Neoadjuvant gemcitabine-cisplatin (GC) for muscle-invasive bladder cancer (MIBC): Does midway CT staging predict for pathologic complete response (pCR)?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.306
    Conference Papers | 2014
    Tan Q; Joshua A; Saggar JK; Man Y; Lee CC M; Wouters BR; Tannock IF, 2014, 'Pantoprazole enhances the activity of docetaxel chemotherapy for solid tumors by inhibition of autophagy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, presented at AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment, CA, San Diego, 26 February 2014 - 01 March 2014, http://dx.doi.org/10.1158/1538-7445.CHTME14-A54
    Conference Papers | 2014
    Vera-Badillo FE; Leibowitz-Amit R; Templeton A; Seah J-A; Sridhar SS; Knox JJ; Tannock I; Joshua AM, 2014, 'Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.159
    Conference Papers | 2013
    Carvajal RD; Sosman JA; Quevedo F; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski T; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Paucar D; Panageas KS; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK, 2013, 'Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419603135&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2013
    Carvajal RD; Sosman JA; Quevedo F; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski T; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Paucar D; Panageas KS; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK, 2013, 'Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335564000012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2013
    Dal Pra A; Zannella V; Glicksman R; Sykes J; Muaddi H; Joshua AM; Wouters BG; Milosevic M; Koritzinsky M; Bristow RG, 2013, 'Metformin and Prostate Cancer Radiation Therapy: Improved Outcomes Due to Enhanced Tumor Oxygenation', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, GA, Atlanta, pp. S170 - S170, presented at 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), GA, Atlanta, 22 September 2013 - 25 September 2013, http://dx.doi.org/10.1016/j.ijrobp.2013.06.440
    Conference Papers | 2013
    Downes MR; Sweet J; Zannella V; Bowes B; Koritzinsky M; Evans AJ; Trachtenberg J; Jewett M; Finelli A; Fleshner N; Pollak M; Joshua AM, 2013, 'The Effects of Metformin on the mTORC Pathway in Prostate Cancer', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MD, Baltimore, pp. 207A - 207A, presented at 102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), MD, Baltimore, 02 March 2013 - 08 March 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000314789301178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2013
    Downes MR; Sweet J; Zannella V; Bowes B; Koritzinsky M; Evans AJ; Trachtenberg J; Jewett M; Finelli A; Fleshner N; Pollak M; Joshua AM, 2013, 'The Effects of Metformin on the mTORC Pathway in Prostate Cancer', in MODERN PATHOLOGY, NATURE PUBLISHING GROUP, MD, Baltimore, pp. 207A - 207A, presented at 102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), MD, Baltimore, 02 March 2013 - 08 March 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000314444401258&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2013
    Hotte SJ; Eisenhauer EA; Joshua AM; Kumar V; Ellard S; Gregg RW; Macfarlane RJ; Winquist E; Torri V; Ruether JD; Basappa NS; Kakumanu AS; North SA; Kollmannsberger CK; Tinker A; Mirchandani D; Tassignon A; Hausman DF; Allan AL; Chi KN, 2013, 'NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419601640&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2013
    Joshua AM; Zannella VE; Downes MR; Bowes B; Koritzinsky M; Sweet J; Trachtenberg J; Jewett MA S; Finelli A; Fleshner NE; Pollak MN, 2013, 'Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419601668&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2013
    Leibowitz-Amit R; Templeton AJ; Atenafu EG; Vera-Badillo FE; Chllamma M; Solow HL; Knox JJ; Tannock I; Sridhar SS; Joshua AM, 2013, 'Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419601656&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2013
    Manokumar T; Aziz S; Rizvi F; Breunis H; Joshua AM; Tannock I; Alibhai SM H, 2013, 'A prospective study examining PROs and other geriatric outcomes in older adults with prostate cancer undergoing chemotherapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419603038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2013
    Margel D; Urbach DR; Lipscombe L; Bell C; Kilkarni G; Austin P; Joshua AM; Fleshner NE, 2013, 'Metformin use and all-cause and prostate-cancer-specific mortality among diabetic men', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419601608&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2013
    Ribas A; Robert C; Daud A; Hodi FS; Wolchok JD; Kefford R; Patnaik A; Hwu W-J; Weber JS; Joshua A; Hersey P; Gangadhar TC; Joseph RW; Dronca RS; Zarour HM; Ebbinghaus S; Gergich K; Li XN; Kang SP; Hamid O, 2013, 'Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419602710&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2013
    Tan Q; Joshua A; Saggar J; Yu M; Lee CM; Koritzinsky M; Wouters BR; Tannock IF, 2013, 'Pantoprazole enhances the activity of chemotherapy for solid tumors by inhibition of autophagy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-3829A
    Conference Papers | 2013
    Templeton A; Wang L; Vera-Badillo F; Attalla M; De Gouveia P; Leibowitz-Amit R; Knox JJ; Moore MJ; Sridhar SS; Joshua AM; Tannock I, 2013, 'From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of American-Society-of-Clinical-Oncology (ASCO), FL, Orlando, 14 February 2013 - 16 February 2013, http://dx.doi.org/10.1200/jco.2013.31.6_suppl.125
    Conference Papers | 2012
    Brade AM; Kim J; Brierley J; Dinniwell R; Wong R; Cho C; Kassam Z; Joshua A; Knox J; Dawson L, 2012, 'Phase I Study of Sorafenib and Whole-liver Radiation Therapy (WLRT) or Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, MA, Boston, pp. S11 - S12, presented at 54th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), MA, Boston, 28 October 2012 - 31 October 2012, http://dx.doi.org/10.1016/j.ijrobp.2012.07.035
    Conference Papers | 2012
    Chi K; Yu EY; Ellard S; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME, 2012, 'A RANDOMIZED PHASE II STUDY OF OGX-427 PLUS PREDNISONE (P) VS. P ALONE IN PATIENTS (PTS) WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (CRPC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, AUSTRIA, Vienna, pp. 297 - 297, presented at 37th Congress of the European-Society-for-Medical-Oncology (ESMO), AUSTRIA, Vienna, 28 September 2012 - 02 October 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000309409001381&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2012
    Chi KN; Hotte SJ; Ellard S; Gingerich JR; Joshua AM; Kollmannsberger CK; Yu EY; Gleave ME, 2012, 'A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2012.30.5_suppl.121
    Conference Papers | 2012
    Chi KN; Hotte SJ; Ellard S; Gingerich JR; Joshua AM; Yu EY; Gleave ME, 2012, 'A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802873&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2012
    Joshua AM; Evren S; Zannella VE; Bowes B; Fleshner NE; Jewett MA S; Finelli A; Evans A; Koritzinsky M; Sweet J; Pollak MN, 2012, 'A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802727&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2012
    Joshua AM; Zannella V; Bowes B; Koritzinsky M; Sweet J; Evans A; Trachtenberg J; Jewett M; Finenlli A; Fleshner N; Pollak M, 2012, 'A phase II study of neoadjuvant metformin in prostatic carcinoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.AM2012-CT-04
    Conference Papers | 2012
    Montgomery RB; Joshua A; Hannah AL; Peterson AC; Lopez C; Gleave ME; Taplin M-E, 2012, 'A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803238&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2011
    Finelli A; Horgan AM; Evans A; Kim TK; Durrant K; Yap S; Cassol CA; Dubinski W; Fleshner N; Jewett MA S; Joshua AM; Sridhar SS; Zlotta A; Knox JJ, 2011, 'Preoperative sorafenib (Sor) and cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)', Vol. 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4668
    Conference Posters | 2011
    Groskopf J; Niraula S; Emmeneger U; Adams L; Tannock I; Sridhar SS; Knox JJ; Day JR; Manthe J; Joshua AM, 2011, 'Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology.', Vol. 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.e15022
    Conference Posters | 2011
    Joshua AM; Cockburn N; Evans A; Squire J; Yoshimoto M; Ludkovski O; Tan S-H; Dobi A; Furusato B; Petrovics G; Srivastava S; Sesterhenn I, 2011, 'Evaluation of PTEN and TMPRSS2-ERG abnormalities in prostate cancer by FISH and immunohistochemistry to address intra- and inter-tissue heterogeneity and disease progression', Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-5074
    Conference Papers | 2011
    Joshua AM; Evans A; Squire J; Yoshimoto M; Ludkovski O; Tan S-H; Dobi A; Furusato B; Petrovics G; Srivastava S; Sesterhenn IA, 2011, 'Evaluation of PTEN and TMPRSS2-ERG Abnormalities in Prostate Cancer by FISH and Immunohistochemistry To Address Intra- and Inter-Tissue Heterogeneity and Disease Progression', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, TX, San Antonio, pp. 393A - 393A, presented at 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology, TX, San Antonio, 26 February 2011 - 04 March 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000291285001328&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2011
    Joshua AM; Evans A; Squire J; Yoshimoto M; Ludkovski O; Tan S-H; Dobi A; Furusato B; Petrovics G; Srivastava S; Sesterhenn IA, 2011, 'Evaluation of PTEN and TMPRSS2-ERG Abnormalities in Prostate Cancer by FISH and Immunohistochemistry To Address Intra- and Inter-Tissue Heterogeneity and Disease Progression', TX, San Antonio, Vol. 24, pp. 393A - 393A, presented at 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology, TX, San Antonio, 26 February 2011 - 04 March 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287282302118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2011
    Joshua AM; Evans A; Squire J; Yoshimoto M; Ludkovski O; Tan S; Dobi A; Furusato B; Petrovics G; Srivastava S; Sesterhenn I, 2011, 'Evaluation of PTEN and TMPRSS2-ERG abnormalities in prostate cancer by FISH and immunohistochemistry to address intra- and intertissue heterogeneity and disease progression.', Vol. 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4651
    Conference Posters | 2011
    Niraula S; Emmeneger U; Adams L; Tannock I; Sridhar SS; Knox JJ; Day JR; Manthe J; Groskopf J; Joshua AM, 2011, 'Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology', Vol. 29, http://dx.doi.org/10.1200/jco.2011.29.7_suppl.59
    Conference Papers | 2011
    Tan Q; Patel K; Lee CM; Zhang J; Joshua A; Koritzinsky M; Wouters BG; Tannock IF, 2011, 'Mechanisms by which pantoprazole, a proton pump inhibitor, enhances the activity of doxorubicin in solid tumors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.AM2011-537
    Conference Posters | 2011
    2011, 'Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology', Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-290
    Conference Abstracts | 2010
    Buckman RA; Berman HK; Sridhar SS; Joshua AM, 2010, 'How much do the side effects of chemotherapy matter? Patients' attitudes to side effects versus a potential loss of duration of remission', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Vol. 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.e19585
    Conference Posters | 2010
    Fahim L; Cockburn N; Joshua A; Warde P; Sweet J, 2010, 'Immunohistochemical Expression of Secretory Clusterin (sCLU) in Benign and Malignant Prostate in the Context of Hormonal Therapy', DC, Washington, Vol. 23, pp. 190A - 190A, presented at 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, DC, Washington, 20 March 2010 - 26 March 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000274582501174&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2010
    Fahim L; Cockburn N; Joshua A; Warde P; Sweet J, 2010, 'Immunohistochemical Expression of Secretory Clusterin (sCLU) in Benign and Malignant Prostate in the Context of Hormonal Therapy', DC, Washington, Vol. 90, pp. 190A - 190A, presented at 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, DC, Washington, 20 March 2010 - 26 March 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000274337300838&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2010
    Niraula S; Tannock I; Pond GR; De Wit R; Eisenberger MA; Joshua AM, 2010, 'Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study.', Vol. 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.4686
    Conference Posters | 2009
    Joshua A; Marrano P; Yoshimoto M; Evans A; Van der Kwast T; Zielenska M; Squire J, 2009, 'Correlations between telomere dysfunction and genomic instability in prostatic carcinogenesis', Vol. 69, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209701804103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2008
    Joshua AM; Broom R; Milosevic M; Jewett M; Evans A; Asa S; Tannock IF; Knox JJ, 2008, 'Rationale and evidence for the use of sunitnib to treat patients with malignant paraganglioma/pheochromocytoma (MPP)', Vol. 26, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.14681
    Conference Posters | 2007
    Joshua AM; Vukovic B; Braude I; Hussein S; Zielenska M; Srigley JR; Evans AJ; Squire JA, 2007, 'Telomere length analysis of high-grade prostatic intraepithelial neoplasia (HPIN) and adjacent stroma predicts outcome in prostate cancer and provides evidence of field carcinogenesis', CA, San Diego, Vol. 20, pp. 154A - 154A, presented at 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, CA, San Diego, 24 March 2007 - 30 March 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000244922401120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2006
    Joshua AM; Mei C; Braude I; Collins T; Vukovic B; Srigley JR; Evans AJ; Squire JA, 2006, 'Developing techniques in high-throughput telomere analysis for the study of prostatic carcinogenesis', GA, Atlanta, Vol. 19, pp. 329A - 330A, presented at 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, GA, Atlanta, 11 February 2006 - 17 February 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000234094502480&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2006
    Joshua AM; Mei C; Braude I; Collins T; Vukovic B; Srigley JR; Evans AJ; Squire JA, 2006, 'Developing techniques in high-throughput telomere analysis for the study of prostatic carcinogenesis', GA, Atlanta, Vol. 86, pp. 329A - 330A, presented at 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, GA, Atlanta, 11 February 2006 - 17 February 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000234207602385&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2006
    Joshua AM; Vukovic B; Braude I; Evans A; Srigley J; Squire JA, 2006, 'Telomere dysfunction in prostatic carcinogenesis.', GA, Atlanta, Vol. 24, pp. 546S - 546S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239009403477&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2006
    Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Prasad M; Fleshner N; Finelli A; Evans A; Sweet J; Squire J; Zielenska M, 2006, 'Detection of novel variant TMPRSS2/ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer.', GA, Atlanta, Vol. 24, pp. 548S - 548S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239009403484&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2005
    Joshua AM; Nordman I; Venkatawaran R; Stockler M; Boyer M; Clarke S, 2005, 'Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC).', FL, Orlando, Vol. 23, pp. 431S - 431S, presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 13 May 2005 - 17 May 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230326602542&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Prostate Cancer, Melanoma, Immuno-Oncology, Metabolomics, Autophagy, Cholesterol Metabolism